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ABSTRACT  
   
Patients with schizophrenia have deficits in sensorimotor gating, the ability to 
gate out irrelevant stimuli in order to attend to relevant stimuli. Prepulse inhibition (PPI) 
of the startle response is a reliable and valid model of sensorimotor gating across species. 
Repeated D2-like agonist treatment alleviates prior PPI deficits in rats, termed a PPI 
recovery, and is observable 28 days after treatment. The aim of the current project is to 
illuminate the underlying mechanism for this persistent change of behavior and determine 
the clinical relevance of repeated D2-like agonist treatment. Our results revealed a 
significant increase in Delta FosB, a transcription factor, in the nucleus accumbens (NAc) 
10 days after repeated D2-like agonist treatment. Additionally, we investigated if Delta 
FosB was necessary for long-lasting PPI recovery and discovered a bilateral infusion of 
dominant-negative Delta JunD prevented PPI recovery after repeated D2-like agonist 
treatment. To further develop the underlying mechanism of PPI recovery, we observed 
that dominant negative mutant cyclic adenosine monophosphate (cAMP) response biding 
element protein (CREB) prevented repeated D2-like agonist-induced Delta FosB 
expression in the NAc. We then compared our previous behavioral and intracellular 
findings to the results of repeated aripiprazole, a novel D2-like partial agonist 
antipsychotic, to determine if repeated D2-like receptor agonist action is a clinically 
relevant pharmacological approach. As compared to previous PPI recovery and Delta 
FosB expression after repeated D2-like agonist treatment, we found similar PPI recovery 
and Delta FosB expression after repeated aripiprazole treatment in rats. We can conclude 
that repeated D2-like agonist treatment produces persistent PPI recovery through CREB 
phosphorylation and Delta FosB, which is necessary for PPI recovery. Furthermore, this 
ii 
pharmacological approach produces behavioral and intracellular changes similar to an 
effective novel antipsychotic. These findings suggest the underlying intracellular 
mechanism for sustained PPI recovery is clinically relevant and may be a potential target 
of therapeutic intervention to alleviate sensorimotor gating deficits, which are associated 
with cognitive symptoms of schizophrenia. 
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Chapter 1 
INTRODUCTION 
Significance  
 Schizophrenia is a prevalent, chronic, and severe mental disorder that causes 
substantial financial, physical, and emotional burdens on society, families, and 
individuals (McEvoy, 2007). While antipsychotic drugs are the preferred and most 
effective treatment option, these drugs produce harmful side effects, resulting in non-
compliance in patients (Tandon, Keshavan, & Nasrallah, 2008). Currently, there is no 
cure or sustainable treatment because the etiology and underlying mechanism of 
schizophrenia are mostly unknown. The outdated theory that a simple neurotransmitter 
dysregulation triggers symptoms does not address the complexity and multifaceted 
characteristics of the disorder; therefore, treatment derived from this theory is not 
adequate. Specifically, all typical and atypical antipsychotics non-specifically block 
dopamine (DA) D2 receptors resulting in side effects, tolerance, and inability to treat 
negative and cognitive symptoms (Lieberman et al., 2005). This problem calls for a more 
sophisticated approach is needed in order to treat and better understand schizophrenia. It 
is believed that dopamine acting via neurons containing D2–like receptors in the nucleus 
accumbens (NAc), affect positive and possibly negative symptoms of schizophrenia 
(Flagstad et al., 2004). These neurons are integral to the understanding of schizophrenia 
symptoms and future potential therapeutic options. Deficits in sensorimotor gating, the 
ability to selectively filter unnecessary stimuli and attend to relevant information, are 
common in patients with schizophrenia and are associated with cognitive symptoms 
(Braff, Geyer, & Swerdlow, 2001). We previously found that repeated D2-like agonist 
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treatment alleviated prior prepulse inhibition (PPI), a measurement of sensorimotor 
gating (Berger, Green, Siegel, Nestler, & Hammer, 2011; Culm & Hammer, 2004; Culm, 
Lugo-Escobar, Hope, & Hammer, 2004). The goal of these experiments is to build on our 
current knowledge of the effect of repeated D2-like agonist treatment on neurons in the 
NAc that regulate PPI. We plan on accomplishing this goal using pharmacological and 
molecular manipulations and observing behavioral and intracellular adaptations. 
Schizophrenia: Prevalence and Impact   
Schizophrenia is a neuropsychiatric disorder that has affected numerous 
individuals throughout history. Currently, an estimated 1 percent of Americans and 24 
million people worldwide live with the disorder (Regier et al., 1993). These statistics 
does not include individuals who are homeless or do not seek treatment, a major problem 
for people with schizophrenia. Prevalence is much higher than onset statistics because 
schizophrenia is a chronic condition (Mueser & McGurk, 2004). In most cases, a person 
is diagnosed with schizophrenia between ages 16 and 30 and will experience sporadic 
episodes of psychosis or ‘psychotic breaks’ throughout their lifetime (de Haan, Linszen, 
Lenior, de Win, & Gorsira, 2003; Wistedt, 1981). However, the progression of 
schizophrenia depends on the individual, environment, and treatment, which contribute to 
the large variability within the schizophrenic population. Schizophrenia is often described 
as one of the most debilitating mental illnesses because of the intensity of symptoms, 
high cost to society, and high rate of mortality (Mueser & McGurk, 2004). For instance, 
patients with schizophrenia have a 2 to 3 times higher rate of premature mortality, 
approximately between 10 to 25 years, than the general population (Crump, Winkleby, 
Sundquist, & Sundquist, 2013; Saha, Chant, & McGrath, 2007). In the United States, 
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high mortality rates are due to various factors, with suicide as the most frequent cause of 
death (Brown, 1997) and cancer as the second most frequent (Tran et al., 2009). 
Incidences of patient suicide are often attributed to depression related to the disorder or a 
side effect of treatment for the disorder (Hawton, Sutton, Haw, Sinclair, & Deeks, 2005). 
These alarming findings have influenced counties to begin experimental health care 
programs to increase suicide prevention and cancer screening in patients with 
schizophrenia (Kisely et al., 2013). In addition to high mortality rates, the intensity of 
symptoms associated with schizophrenia greatly contributes to the severity of this 
disorder. 
Symptoms of Schizophrenia  
Schizophrenia is a complex disease that is characterized by multiple different 
behaviors, which have been deconstructed into symptom categories to better diagnose, 
research, and treat the disorder. Schizophrenia includes varying degrees of positive, 
negative, and cognitive symptoms. Positive symptoms are psychotic behaviors that are 
not observed in the normal population and are usually the reason an individual or family 
member seeks treatment because the resulting behaviors are bizarre, distinct, and deviant 
from normal behaviors (Kimhy et al., 2013). The frequency and intensity of these 
symptoms vary in each individual throughout their life and include hallucinations, 
delusions, thought disorders, and movement disorders (Mueser & McGurk, 2004). 
Positive symptoms respond well to antipsychotic medication as compared to the other 
symptoms of schizophrenia (Risch, 1996). Negative symptoms of schizophrenia are more 
difficult to distinguish as part of the disorder because they are mistaken for depression or 
other conditions (Mueser & McGurk, 2004). These symptoms are associated with 
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disruptions to normal emotion or behavior and include flat affect, anhedonia, alogia, lack 
of motivation, and decreased social interactions. Finally, cognitive symptoms include 
poor executive functioning, trouble focusing or paying attention, and working memory 
deficits. The severity of cognitive symptoms is highly predictive of a patient’s long-term 
prognosis, more than the positive symptoms (Green, 1996). As compared to positive 
symptoms, negative and cognitive symptoms are more resilient to antipsychotic 
medications. Specific brain regions and circuitry appear to mediate each group of 
symptoms (discussed in detail later) and this may explain the variance of antipsychotic 
medication among the symptoms.  
The symptoms of schizophrenia can be overwhelming and can affect an 
individual’s ability to work or financially contribute to society (McEvoy, 2007). In the 
United States in 2002, the estimated cost of schizophrenia was $62.7 billion. These costs 
are estimated from the direct and indirect financial effects of the disorder. Direct costs 
include treatments provided by inpatient and outpatient facilities, criminal justice, and 
medication costs. Indirect costs include productivity loss by patients with schizophrenia, 
family members, and caregivers (McEvoy, 2007). Family members and caregivers of 
patients with schizophrenia can be vulnerable to increased stress and often need support 
themselves (Scazufca & Kuipers, 1999).  
Schizophrenia is a chronic and severe disorder that can be costly to an individual 
and community. The expression, complexity, and intensity of symptoms vary within the 
schizophrenic population and antipsychotics also vary in their effectiveness to treat 
symptoms. Treatment is difficult because the etiology and underlying mechanisms 
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responsible for schizophrenia are not completely understood, however there have been 
significant gains in research since Dr. Emile Kraepelin defined the disorder in 1887.  
Etiology of Schizophrenia  
Schizophrenia is caused by several factors including genetic and environmental 
influences. Research into the etiology of schizophrenia often focuses on genetic 
contributions because 10 percent of people with a first-degree relative with the disorder 
will develop schizophrenia as compared to 1 percent of the general population (Baron et 
al., 1985). Additional support is found in twin studies where identical twins have a high 
concordance rate of 40 to 65 percent (Cardno & Gottesman, 2000). Schizophrenia is not 
caused by a single gene mutation or deletion; rather researchers believe hundreds of 
different genes contribute to schizophrenia symptoms (Fanous et al., 2012). However, 
individuals with the disorder have higher rates of rare genetic mutations and single-
nucleotide polymorphisms (SNPs) near genes involved in neurodevelopment, 
neuroprotection, or neurotransmission (Fanous et al., 2012; Walsh et al., 2008). Although 
schizophrenia has a strong genetic component, genetics alone cannot predict the disorder. 
Since the concordance rate among identical twins is not 100 percent, many believe 
environmental factors are also involved in the occurrence of this disorder.                                                                                                       
A variety of environmental factors have been associated with the onset of schizophrenia. 
Early environmental insults, such as prenatal infections or malnutrition, maternal 
substance misuse, and obstetric complications are more common in the schizophrenic 
population as compared to the general population (Lieberman et al., 2001). There is 
growing evidence that social and psychological factors, such as stressful life events, 
ethnicity, urbanization, childhood trauma, and illicit drug use are also associated with 
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schizophrenia (Howes et al., 2004). This is supported by studies that found an increased 
risk of schizophrenia after an urban birth and upbringing as compared to rural residents 
(Allardyce et al., 2000). Cannabis is the most common illicit drug used by patients with 
schizophrenia and associated with an earlier age of onset (Di Maggio, 2001). Researchers 
are interested in this association because it may give insight into the underlying 
neurotransmission of schizophrenia and its potential precursors. The environmental 
factors listed previously are highly associated with schizophrenia, however because many 
of these studies are correlational it is difficult to determine the causal relationship and 
there may be additional contributing factors.  
The identification of genetic and environmental factors that may produce 
schizophrenia has led to the “Two-Hit” hypothesis of schizophrenia. This hypothesis 
suggests that a prenatal genetic or environmental “first hit” disrupts brain development 
and increases vulnerability in the individual. The “second hit” is usually an 
environmental insult that compromises the functional integrity of the brain and exposes 
the vulnerability caused by the “first hit” (Maynard, Sikich, Lieberman, & LaMantia, 
2001). This theory addresses the discrepancy in full concordance of the disorder among 
twins and the high association with environmental factors. Some potential mechanisms 
include early disruptions to central nervous system (CNS) development; specifically in 
cell-signaling pathways involved in induction, morphogenesis, and differentiation. These 
disruptions are then “primed” for later insults on the same pathways that are redeployed 
for neural maintenance during adolescence or early adulthood (Maynard et al., 2001). 
Research is still ongoing examining the validity of the “Two-Hit” hypothesis, however 
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previous research examining cell-signaling pathways has provided some evidence of 
these abnormalities that underlie symptoms of schizophrenia.  
Neurotransmitter Systems Underlying Schizophrenia  
Schizophrenia is a multifaceted disorder; therefore multiple brain regions, 
neurotransmitter systems, and cell-signaling cascades are involved in the underlying 
mechanisms. Specific brain regions or neurotransmitters systems are more closely 
associated with certain symptoms as compared to others. However, there is no simple 
direct region or system relationship with one symptom or behavior because many of these 
neurotransmitter systems are complex and interrelated. With that being said, the DA 
system, specifically the DA mesolimbic pathway, has been a focal point schizophrenia 
research and has been associated with positive and negative symptoms of schizophrenia. 
Several neurotransmitter systems are involved in schizophrenia. DA and 
glutamate are the most examined, thus resulting in the DA and glutamate hypothesis of 
schizophrenia. DA has been a focal point of schizophrenia research and treatment since it 
was discovered that chlorpromazine attenuated psychotic symptoms by antagonizing the 
D2 receptor (Seeman & Lee, 1975). DA is a modulating neurotransmitter that has been 
implicated in a multitude of behaviors and psychological disorders.  
Dopamine Circuitry Involved in Schizophrenia  
DA is produced in the midbrain within cell bodies in the substantia nigra and 
ventral tegmental area (VTA). The nigrostriatal pathway projects from the substantia 
nigra to the basal ganglia or striatum and controls motor function and movement. 
Compensation in the nigrostriatal pathway after antipsychotic medication contributes to 
motoric side effects (discussed later). The mesolimbic pathway projects from the VTA to 
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the NAc and is involved in many behaviors related to motivation, drug abuse, and 
schizophrenia. The mesolimbic pathway synapses onto gamma Aminobutyric acid 
(GABA) medium spiny neurons, a class of GABAergic cells, and is hyperactive in 
schizophrenia patients (Lee & Seeman, 1980).  Hyperactivity within this pathway is 
believed to induce the positive symptoms such as hallucinations and delusions (Creese, 
Burt, & Snyder, 1976). This was first concluded after observations that drugs that 
increased DA release enhanced or produced positive symptoms and drugs that decrease 
dopamine decreased or stop positive symptoms (Meltzer & Stahl, 1976). These 
observations contributed to the DA hypothesis of schizophrenia or more specifically the 
mesolimbic DA hypothesis of positive symptoms of schizophrenia (Stahl, 2007). This 
overactivity can be expressed as excess of DA release from the nerve terminals, more DA 
receptors, supersensitivity of DA receptors, or a hyperactivity of the DA receptor-
signaling cascade. Conflicting findings of DA influx or increased D2 receptors detected 
by position emission tomography (PET) led to doubts about the DA hypothesis 
(Nordstrom, Farde, Eriksson, & Halldin, 1995). However, significant increases in D2 
receptor density were found after single photon emission computer tomography (Kelz et 
al.) in early-diagnosed schizophrenia patients before exposure to antipsychotic drugs 
(Corripio et al., 2011), which supports the hypothesis. In addition to the mesolimbic 
pathway, the mesocortical pathway also projects from the VTA but sends axons to areas 
of the prefrontal cortex (PFC), specifically the dorsolateral prefrontal cortex (DLPFC), 
synapsing on pyramidal neurons that may have a role in mediating cognitive and negative 
symptoms (Morrissette, 2011). The specific role of the mesocortical pathway in 
regulating cognitive and negative symptoms is still not clearly understood, but many 
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believe the symptoms are due to a deficit in DA activity in the pathway to the DLPFC 
(Morrissette, 2011). While DA pathways were the first identified contributors to 
schizophrenia symptoms, increasing evidence suggests they are the result of 
pathophysiology within the glutamate system; therefore it is imperative to understand the 
interconnections between the DA hypothesis and the expanding glutamate hypothesis of 
schizophrenia.  
Glutamate Regulation of Dopamine Transmission  
 Recently, glutamate has become the focus of research and resulting theories to 
explain the pathophysiology of schizophrenia. Glutamate is the major excitatory 
neurotransmitter in the brain and glutamate projections interact with the dopamine 
projections in the PFC, NAc, and VTA as well as other key brain areas associated with 
schizophrenia. Glutamate involvement was first hypothesized after phencyclidine (PCP), 
an N-methyl-D-aspartate receptor (NMDAR) antagonist, produced positive, negative, and 
cognitive deficits in users and exacerbated symptoms in schizophrenic patients (Itil, 
Keskiner, Kiremitci, & Holden, 1967). Also, reduced glutamate was found in 
schizophrenic patients’ cerebral spinal fluid (CSF) as compared to other patients (Kim, 
Kornhuber, Schmid-Burgk, & Holzmuller, 1980). These observations supported the 
glutamate hypothesis, that NMDAR hypofunction disrupts glutamate pathways and 
results in positive, negative, and cognitive symptoms of schizophrenia (Stahl, 2007). The 
glutamate hypothesis does not negate the dopamine hypothesis of schizophrenia; rather it 
is believed the two hypothesizes are dependent on each other through a circuitry based 
explanation.  
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 Glutamate can have actions at nearly all neurons in the brain; however, there are 
five main glutamate pathways relevant to schizophrenia. The cortical brainstem 
glutamate projection projects from the cortical pyramidal neurons to brainstem 
neurotransmitter centers and regulates neurotransmitter release. The corticostriatal 
glutamate pathway projects from the prefrontal cortex to the striatum. Thalamocortical 
glutamate pathways ascend from the thalamus and innervate the cortex. Corticothalamic 
glutamate pathways descend from the prefrontal cortex to the thalamus. Finally, 
intracortical pyramidal neurons communicate with each other via corticocortical 
glutamatergic pathways.  The pathway believed to be most critical to schizophrenia and 
specifically DA modulation is the corticobrainstem pathway, which projects from the 
cortical pyramidal neurons, primarily in lamina 5, to brainstem neurotransmitter cell 
bodies, including the raphe nucleus for serotonin (5-HT), VTA and substantia nigra for 
DA, and locus coeruleus for norepinephrine (NE). In the DA system, the 
corticobrainstem glutamate pathway is usually the “break” for the mesolimbic pathway 
via its excitatory inputs onto GABA interneurons synapsing onto DA neurons and the 
“accelerator” for the mesocortical pathway via its direct synapse onto DA neurons. 
Therefore, NMDAR hypofunction in the PFC dysregulates the glutamatergic 
corticobrainstem pathway to the VTA resulting in lack of stimulation onto GABA 
interneurons and hyperactivity of the mesolimbic dopamine pathway while at the same 
time lack of direct stimulation onto the DA mesocortical pathway produces hypoactivity 
(Stahl, 2007). Through their interconnections, glutamate and DA both contribute to the 
positive, negative, and cognitive symptoms of schizophrenia.  
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Dopamine and the Nucleus Accumbens  
 There is an existing theory that hyperactivity of the mesolimbic dopamine 
pathway is responsible for the positive symptoms and the hypoactivity of the 
mesocortical dopamine pathway is responsible for the negative symptoms. This 
explanation is oversimplified as evidenced by the complex interactions and modulations 
of glutamate and new evidence suggesting the striatum may also be involved in the 
cognitive or negative symptoms. For example, high distractibility or sensory overload is 
often included within cognitive or negative symptoms and the striatum is believed to 
modulate the “filter” by which sensory information is processed (Simpson, Kellendonk, 
& Kandel, 2010). The cortico-striatal-thalamic-cortical (CSTC) loop underlies the 
regulation of sensory overload and the thalamus is usually identified as the “thalamic 
sensory filter”, however the striatum is also involved in this process. Within the striatum, 
the dorsal striatum is more closely associated with the CSTC loop; however, the ventral 
striatum may also be involved in regulation of behaviors related to cognitive and negative 
symptoms.  
 Within the ventral striatum, the NAc has been implicated in several behavioral 
and cognitive functions, such as translation of stimuli to behavioral response (Mogenson, 
1980 #2902), coding of reward and reward expectation (Koob, Sanna, & Bloom, 1998), 
impulse control (Cardinal, Pennicott, Sugathapala, Robbins, & Everitt, 2001), and 
instrumental learning (Balleine & Killcross, 1994). The NAc is often considered the point 
of connection between sensory and associative brain areas processing and evaluating 
stimuli and the motor systems mediating responses to these stimuli (Mogenson, 1980 
#2902). Specific to schizophrenia, the NAc is critical for sensorimotor gating, which may 
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lead to sensory flooding and cognitive fragmentation (Swerdlow, Braff, Taaid, & Geyer, 
1994). The NAc has also been implicated in the negative symptoms of schizophrenia, 
where schizophrenic patients have decreased blood flow in the NAc when reporting 
feelings of anhedonia (Crespo-Facorro et al., 2001). 
 In summary, hyperactivity of the mesolimbic dopamine pathway via 
dysregulation of the corticobrainstem glutamate pathway produces positive symptoms of 
schizophrenia. Within the mesolimbic pathway, the NAc may also be involved in 
negative and cognitive symptoms of schizophrenia (Howes & Kapur, 2009). Due to 
glutamate’s influence on dopamine, researchers are beginning to examine drugs that 
target glutamate receptors as possible therapeutic targets for schizophrenia treatment. 
However, since all current antipsychotic drugs target D2 receptors it is important to 
understand these receptors and their role in schizophrenia and treatment.  
Dopamine Receptors  
Endogenous DA can bind to five different G-protein coupled receptors in the 
mammalian brain, D1, D2, D3, D4, and D5. These receptors are categorized into two 
groups, based on the resulting activation or inhibition of adenylate cyclase following 
stimulation of a particular receptor subtype. Adenylate cyclase is an important part of the 
G-protein signaling cascade that can initiate intracellular changes via activation of the 
cyclic adenosine monophosphate (cAMP) pathway. The D1-like receptors include the D1 
and D5 and are Gs protein coupled receptors that and activate adenylate cyclase. The D2-
like receptors include the D2, D3 and D4 and are Gi protein coupled receptors that and 
inhibit adenylate cyclase. Furthermore, D2 receptors are a heterogeneous population 
comprised of short, D2S, and long D2L isoforms (De Mei, Ramos, Iitaka, & Borrelli, 
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2009). D2S receptors are often described as autoreceptors and generally located on 
presynaptic DA neurons, specifically cell soma/dendrites and regulates transmitter 
synthesis and release (Roth, 1979). D2S receptors are more sensitive as compared to D2L 
receptors as evidenced by low doses of DA agonists preferentially stimulate D2S (White 
& Wang, 1986). D2L are located on the postsynaptically where D2L mRNA are contained 
within 90 percent of total D2 receptor containing neurons in the striatum (Neve, Neve, 
Fidel, Janowsky, & Higgins, 1991).  
D2-like receptors are located throughout the brain, mainly in regions receiving DA 
projections. In the striatum, D2-like receptors are located ubiquitously throughout the 
dorsal and ventral regions; however this is only true for D2 receptors as D3 receptors are 
specifically located in the ventral striatum (Curran & Watson, 1995). D2-like receptors in 
the NAc are mainly located on GABAergic medium spiny neurons, which receive 
dopaminergic input from the VTA and glutamatergic input from PFC, thalamus, 
hippocampus, and basolateral amygdala. NAc medium spiny neurons project out to the 
ventral pallidm (VP), lateral hypothalamus, and mesencephalic dopaminergic areas 
(Groenewegen, Berendse, & Haber, 1993).  
D2-like receptors were first associated with schizophrenia after the discovery of 
the D2 antagonist action of antipsychotics (Seeman & Lee, 1975). Furthermore, the 
clinical antipsychotic potencies of these drugs are directly related to their binding affinity 
for the D2 receptor (Kapur et al., 2002). Also, post-mortem examination of the brains of 
schizophrenic patients, who had not taken antipsychotic medication for several years 
prior to death, displayed significant increases in D2 receptors; specifically, this increase 
was observed in the NAc which may be a compensatory mechanism due to an increased 
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amount of endogenous DA in the area (Kestler, Walker, & Vega, 2001). This finding 
would support the DA hypothesis of schizophrenia, specifically the hyperactivity of the 
mesolimbic pathway, however increases of D2-like receptors in the NAc have been 
difficult to replicate in patients with schizophrenia. Researchers have also hypothesized 
that D2-like receptors might contribute to positive symptoms through a change in receptor 
function as compared to amount of receptors in the NAc. Patients with schizophrenia are 
supersensitive to their own endogenous DA and have exacerbated symptoms when 
challenged with dopamine-stimulating drugs (Lieberman, Kane, & Alvir, 1987). This 
suggests there is an increased amount of D2 receptors in a high affinity state (D2High) in 
schizophrenic patients. Although this was found in animal models of schizophrenia, this 
has not been replicated in humans (Seeman et al., 2005).  
The exact mechanism of how D2 receptor function in the NAc is related or 
causative of schizophrenic symptoms is unknown. We do know that D2 -like receptors are 
somehow involved in the alleviation of positive symptoms of schizophrenia from the 
direct relationship of D2 receptor affinity and clinical effectiveness (Kapur et al., 2002). 
However, there are negative side effects associated with current antipsychotics, therefore 
newer antipsychotic with different pharmacological targets or mechanisms are needed.  
Antipsychotic Drugs  
 Antipsychotic drugs are characterized as either typical or atypical based on their 
pharmacological properties. Typical antipsychotics antagonize the D2 receptor and block 
muscarinic cholinergic, histamine-1, or alpha-1 adrenergic receptors. These drugs are 
effective in treatment of positive symptoms, but have little effect on negative or cognitive 
symptoms. The first antipsychotic was developed as an anesthetic (Lacomme, Laborit, Le 
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Lorier, & Pommier, 1952), which can induce neurolepsis, an extreme form of slowness or 
absence of motor movements. Since typical antipsychotics non-specifically antagonize 
the D2 receptor, they are effective at targeting the dysregulation in the mesolimbic 
pathway. In the nigrostriatal pathway, continued use of typical antipsychotics can cause 
an up-regulation of D2 receptors in the dorsal striatum. This up-regulation disrupts basal 
ganglia functioning resulting in extra pyramidal symptoms (EPS), such as tardive 
dyskinesia, a common side effect of antipsychotics. Typical antipsychotics are still used 
today, but usually not for long-term treatment. These findings lead to the development of 
a second class of drugs with the goal to decrease EPS.  
Atypical antipsychotic drugs vary within their pharmacological properties, 
however they do share some similarities. This second generation of antipsychotic drugs 
mostly decreases EPS and is slightly more effective at treating negative symptoms. The 
pharmacological property of atypical antipsychotics often includes antagonizing D2 and 
5-HT2A receptors. Additional pharmacological mechanisms such as D2 antagonist with 
rapid dissociation or 5-HT partial agonist action are also involved with the main goal to 
decrease EPS. Atypical antipsychotics target specific 5-HT receptors that modulate DA 
projections to prevent D2 receptor up-regulation. Although atypical antipsychotics are a 
significant improvement from typical antipsychotics, refinements are still needed. 
Specifically, antipsychotic drugs are effective at reducing positive symptoms; however, 
the attenuation of cognitive deficits is less effective (Greengard, 2001). The majority of 
antipsychotics still produce side effects, such as lethargic feelings, which results in the 
discontinuation of medication generally within 6 months (Stroup et al., 2009).  These side 
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effects and lack of complete alleviation of all symptoms demonstrates a need for a novel 
therapeutic approach for the treatment of schizophrenia.  
As compared to the traditional D2 antagonist property of typical and atypical 
antipsychotics, a new third generation antipsychotic is unique in that it has D2 partial 
agonist actions. In 2002, the first D2 partial agonist drug that was approved for treatment 
of schizophrenia was aripiprazole. Aripiprazole also has higher affinity for D2 receptors 
than endogenous dopamine, and has reduced efficacy within the neuron as compared to 
typical and atypical antipsychotic (Nordquist et al., 2008). Therefore, the characteristics 
of partial agonists make aripiprazole ideal for targeting the hyperactivity in one region 
and the hypoactivity in another region without producing an upregulation of receptors in 
the nigrostriatal pathway. In clinical trials, patients report fewer side effects following 
aripiprazole administration as compared to other antipsychotics and the drug has been 
somewhat effective at treating negative and cognitive symptoms (Fleischhacker, 2005). 
Antipsychotic pharmacological profiles are constantly being revised to increase 
effectiveness and decrease side effects. Each drug improves upon previous generations; 
however some patients still report side effects and lack of effectiveness. This novel 
antipsychotic mechanism and resulting positive clinical findings support the theory that a 
new pharmacological approach is needed in treatment of schizophrenia. Furthermore, 
using a new pharmacological approach and examination of the resulting behavioral and 
intracellular changes may give us new insight into the underlying mechanism of 
schizophrenia. The most widely used tool for investigating the underlying mechanisms of 
schizophrenia is the use of animal models of the disorder.  
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Creating a Valid Model of Schizophrenia  
 Animal models are currently the most efficient and ethical way to examine the 
underlying mechanisms responsible for schizophrenia. However, schizophrenia is an 
idiopathic disease with a multitude of behavioral and pathophysiological factors thus 
making it difficult to replicate the entire disorder in an animal (Jentsch & Roth, 1999). 
Also, the diagnostic categories in psychiatry are constantly evolving; therefore producing 
an animal that is similar in the underlying mechanism and behavioral symptoms 
associated with the disease is extremely difficult. Researchers that claim to have a 
complete animal model are constantly justifying the lack of similarities (i.e., face 
validity) between their model and the endogenous disorder. The simplest approach is the 
development of animal models that mimic only specific symptoms associated with the 
disorder, rather than attempting to generate the entire disorder. Multiple criteria have 
been used to examine the strength of an animal model. When using the above approach 
with the goal to examining the underlying mechanism of the human condition the model 
must satisfy two criteria in order to establish its value in basic neurobiological research: 
reliability and predictive validity (Markou & Geyer, 1995).  
 Reliability refers to the consistency and stability with which the variables of 
interest are observed. In animal models, this means the ability to manipulate the 
independent variable with a high degree of precision and the ability to measure the 
dependent variables objectively. Also, the ability to reproduce the effects of the 
manipulations in similar conditions must be satisfied by the model (Markou et al., 1993). 
There are many types of validity including: predictive, construct, convergent, etiological, 
and face validity. Depending on the purpose of the test the experimenter wishes to 
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validate, different types of validity are relevant. For the purpose of basic neurobiological 
research, predictive validity and construct validity are generally used to validate an 
animal model. An animal model has predictive validity in that it allows one to make 
predictions based on the performance of the model. Construct validity is the accuracy 
with which the test measures what it is intended to measure, however in animal models of 
schizophrenia, exactly what a test is supposed to measure is constantly changing as the 
scientific field is being updated (Markou & Geyer, 1995).  
 There are multiple types of animal models of schizophrenia including but not 
limited to genetic, pharmacological, and non-pharmacological models. For the purpose of 
this paper, we will focus on the models most relevant to the included experiments.  
NMDAR Antagonist Animal Model of Schizophrenia  
Noncompetitive antagonists of the NMDAR, including PCP and ketamine, seem 
to be able to induce both positive and negative symptoms of schizophrenia, which include 
cognitive dysfunction in normal humans (Javitt & Zukin, 1991). These drugs also 
exacerbate both positive and negative symptoms of schizophrenia (Itil et al., 1967). Other 
pharmacological animal models, such as the psychostimulant and hallucinogen models, 
are effective at mimicking the positive symptoms of schizophrenia and some of the 
underlying mechanisms. These models have high reliability and some predictive validity 
to the human disorder; however they are not as widely used because they lack the ability 
to induce negative or cognitive symptoms. From these findings, many researchers believe 
PCP administration is the most complete pharmacological model of schizophrenia 
because it induces analogous positive, negative, and cognitive symptoms in the rat 
(Jentsch & Roth, 1999). PCP-or ketamine-induced animal models of schizophrenia have 
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high reliability and face validity in that acute PCP or ketamine induces behaviors in rats 
that mimic behaviors observed in schizophrenic patients, such as social withdrawal, 
sensorimotor gating deficits, and lack of motivation (Sams-Dodd, 1999; Swerdlow, 
Bakshi, & Geyer, 1996). Furthermore, NMDAR antagonism induces glutamate and DA 
changes that are believed to be the same in schizophrenic patients (Jentsch & Roth, 
1999). The predictive validity of this model is interesting in that typical antipsychotics, 
such as haloperidol, generally do not alleviate PCP or ketamine induced behavioral 
responses; however atypical antipsychotics, such as clozapine, consistently alleviate these 
behaviors in clinically relevant doses (Swerdlow et al., 1996; Swerdlow, Bakshi, Waikar, 
Taaid, & Geyer, 1998).  
DA Receptor Agonist Animal Model of Schizophrenia  
 Psychostimulants, such as amphetamine or cocaine, are the most widely used 
pharmacological model of schizophrenia. This model was first used after observations in 
humans that developed psychosis after acute or chronic exposure to these drugs (Segal, 
Geyer, & Schuckit, 1981). In animals, psychostimulants increase dopamine 
neurotransmission into the striatum; however too much dopamine release into the dorsal 
striatum can results in stereotypic behaviors. This behavior was once believed to be 
mimicking the negative symptoms of schizophrenia, however it is now believed the 
behavior is more similar to the side effects of antipsychotic medication (Geyer & 
Moghaddam, 2002). Another potential drawback in using this model is the development 
of tolerance after repeated administration and high dosages that are needed to induce 
behavioral changes. These results can affect the face validity of the model because they 
are not observed in schizophrenic patients. However, the model is still widely used and 
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other more specific DA agonists, such as apomorphine, are often used to induce deficits 
to test antipsychotic efficacy (Geyer & Moghaddam, 2002).  
Sensorimotor Gating Deficits  
There are several behavioral tests that are used to exam the validity of an animal 
model. The specific behavioral task used is dependent on the question being examined. 
Some behaviors, such as locomotion, do not correspond to symptoms of schizophrenia, 
but do measure pharmacological stimulation or anti-dopaminergic activity of neuroleptics 
(Geyer & Moghaddam, 2002). However, other behavioral measures, such as disruption of 
prepulse inhibition (PPI) or impaired attentional set-shifting, mimic schizophrenia 
behaviors (Geyer & Moghaddam, 2002). 
A common observation in schizophrenic patients is the inability to filter or gate 
the majority of sensory and cognitive stimuli they perceive (McGhie & Chapman, 1961; 
Neale & Cromwell, 1970). Several sensorimotor gating mechanisms converge to allow an 
individual to successfully gate out irrelevant stimuli in order to attend to relevant stimuli 
(Braff & Saccuzzo, 1985). Impairments in sensorimotor gating can lead to sensory 
overload and cognitive fragmentation (Braff, Geyer, M.A., 1990). The theory of 
sensorimotor gating has been operationalized in both humans and animals using PPI and 
gating of P50 event-related potentials (ERPs). The ability to conduct very similar tests in 
humans and animals strengthens the generalizability and face validity of this model.  
Prepulse Inhibition of the Startle Response  
The PPI paradigm is based on the finding that a weak pre-stimulus presented 30-
500 msec prior to a startling stimulus reduces or “gates” the amplitude of the startle 
response. PPI is a robust phenomenon with high reliability because PPI is observable 
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within and between multiple sensory stimuli using a variety of parameters and does not 
require learning or comprehension of instructions (Braff & Geyer, 1990). Furthermore, 
PPI deficits have been observed in schizophrenic, schizotypal, and psychosis-prone 
people (Cadenhead, Geyer, & Braff, 1993). Individuals with disorders that are believed to 
have sensorimotor gating deficits, such as Tourette’s Syndrome, Obsessive Compulsive 
Disorder (OCD), and Attention Deficit Hyperactivity Disorder (ADHD), as evidenced by 
more individuals with these disorders also display PPI deficits as compared to the general 
population (Swerdlow, 2001, 2005). PPI deficits are significantly correlated with deficits 
in habituation (Geyer & Braff, 1987), distractibility (Karper et al., 1996) and thought 
disorder (Perry, Geyer, & Braff, 1999). These findings support the theory that 
sensorimotor gating deficits are related to cognitive deficits observed in patients with 
schizophrenia.  
In rats, direct or indirect DA or noncompetitive NMDAR antagonists can produce 
PPI deficits (Geyer, Swerdlow, Mansbach, & Braff, 1990). DA agonist-induced deficits 
are alleviated by typical and atypical antipsychotics (Geyer et al., 1990). Furthermore 
strong correlations have been found between clinical efficacy of antipsychotic drugs in 
schizophrenic patients and their ability to attenuate DA agonist induced PPI deficits in 
rats (Swerdlow et al., 1994).  
The neural circuitry that regulates PPI involves more regions and pathways than a 
simple brain stem startle response. The brainstem loop quickly connects the incoming 
stimulus to the outgoing motoric response and is mediated by inhibitory projections from 
the ventral pallidum (VP) and NAc. GABAergic projections from the NAc project 
directly to the pedunculopontine nucleus (PPTg) and the VP. Before sending GABA to 
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the PPTg and closing the “gate”, the NAc receives glutamatergic projections from the 
hippocampus, PFC, amygdala, and cingulate gyrus as well as dopamine projections from 
the VTA. These findings have led researchers to label the NAc the “hub” in PPI 
regulation due to its connecting forebrain and limbic structures (Swerdlow, Geyer, & 
Braff, 2001). This is supported by PPI disruption after NAc lesions or direct infusion of a 
D2 receptor agonist (Wan & Swerdlow, 1993).  The PPI brain circuit overlaps with key 
brain regions involved in the underlying mechanisms of schizophrenia and antipsychotic 
treatment. Taken together, the NAc is a significant brain area in PPI regulation, 
symptoms of schizophrenia, D2 receptor localization, and antipsychotic target.  
PPI is the objective and quantitative assessment of sensorimotor gating. As 
compared to a comprehensive model of schizophrenia, PPI deficits observed in animals 
after DA agonist treatment mimics a specific symptom associated with the disorder. This 
model is robust and reliable across different stimulus, parameters, and species. PPI 
deficits are also observed in patients with schizophrenia and antipsychotics block these 
deficits, thus contributing to the face and predictive validity of the model. Therefore, PPI 
is the optimal tool to investigate different pharmacological approaches and the resulting 
behavior and underlying mechanisms.  
Repeated D2-like Receptor Agonist Treatment  
In experimental animals, DA agonists in the NAc can produce PPI deficits in 
rodents and is a useful model to investigate the underlying mechanisms of schizophrenia 
(Swerdlow, Caine, & Geyer, 1992). Repeated exposure to cocaine and amphetamine can 
induce behavioral sensitization via increases of DA neurotransmission in the NAc 
(Kalivas & Stewart, 1991) and has been used to model neuroadaptive changes of 
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schizophrenia (Robinson & Becker, 1986). Based on these previous findings, it can be 
hypothesized that repeated cocaine administration, an indirect DA receptor agonist, 
would exacerbate PPI deficits, however an alleviation of previous PPI deficits was 
observed (Byrnes & Hammer, 2000). Neurons in the NAc containing D2-like receptors 
are believed to mediate PPI as evidenced by direct infusion of D2-like receptor agonist 
into the NAc disrupted PPI as compared to no effect after infusion of D1 receptor agonist 
(Wan & Swerdlow, 1993). Therefore, we believe “PPI recovery” is D2-like receptor 
mediated and repeated treatment with D2-like receptor agonists, quinpirole or ropinirole, 
produced PPI recovery (Culm & Hammer, 2004). These findings are significant because 
they suggest a pharmacological approach alternative to D2 receptor antagonism that can 
alleviate PPI deficits. 
PPI recovery is observed 28 days after D2-like agonist treatment (Berger et al., 
2011). This behavioral change in the absence of the drug suggests the prior repeated 
treatment of D2-like receptor agonist initiated a long-lasting neuroadaptation that persists 
independent of drug stimulation. It is critical to determine the underlying mechanism 
responsible for PPI recovery because D2-like receptor containing neurons within the NAc 
are involved in the treatment of schizophrenia and determining possible molecular 
changes could have therapeutic implications.  
Underlying Mechanism of PPI Recovery  
 Our previous observation that rats exhibit recovery of sensorimotor gating after 
repeated treatment with quinpirole or ropinirole compels us to explore the underlying 
mechanisms that may be responsible for this behavioral effect. A plausible mechanism 
for PPI recovery could be a compensatory effect, specifically an increase or decrease in 
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the number of receptors to regain homeostasis. Another possible mechanism could be 
tolerance or desensitization of D2-like receptor function. However, there was no 
significant change found in the amount of G-protein in the NAc or change in G-protein 
function after repeated D2-like receptor agonist treatment (Culm & Hammer, 2004). 
These findings suggest a change in intracellular mechanisms may contribute to PPI 
recovery.  
As mentioned previously, acute stimulation of D2-like receptors results in the 
inhibition of adenylate cyclase, however repeated stimulation of these receptors increase 
cAMP, known as sensitization of adenylate cyclase (Watts & Neve, 2005). This 
sensitization of adenylate cyclase can activate the cAMP-signaling transduction cascade 
thus resulting in down-stream intracellular activation or modifications. An important 
transcription factor, cAMP response element binding (CREB) protein, is activated via 
phosphorylation at Serine-133 by several signal transduction cascades, including cAMP 
activated protein kinase A (PKA). Increases in CREB in the NAc were observed after 
chronic psychostimulants and opiate administration (Carlezon et al., 1998; Konradi, Cole, 
Heckers, & Hyman, 1994). CREB binds to the cAMP response element (CRE) in many 
gene promoters, including several growth factors, enzymes, and structural proteins, as 
well as other transcription factors (Lonze & Ginty, 2002). In the NAc, CREB and 
downstream targets are implicated in neural plasticity after chronic drug administration as 
evidenced by modulation of self-administration and relapse (McClung & Nestler, 2008). 
Therefore, PKA activity and CREB phosphorylation may induce neural plasticity as 
evidenced by PPI recovery.  
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Repeated D2-like agonist treatment results in increased PKA activity and 
phosphorylation of CREB (Culm et al., 2004). Furthermore, blocking phosphorylation of 
CREB with a dominant negative mutant CREB virus infused into the NAc prevented PPI 
recovery (Berger et al., 2011). These findings were observed immediately after 28 days 
of repeated D2-like agonist treatment. Phosphorylation of CREB was not observed 28 
days after repeated treatment, therefore phosphorylation of CREB contributes to PPI 
recovery during treatment, but not PPI recovery after treatment. It is plausible to 
hypothesize that and additional longer lasting intracellular component may be involved in 
the mechanism responsible for PPI recovery 
ΔFosB: Possible Regulator of Persistent PPI Recovery 
In contrast to the transient expression of CREB phosphorylation observed after 
repeated D2-like agonist treatment, ΔFosB has a significantly longer half-life and remains 
present for weeks to months after induction (Nestler, 2008). ΔFosB is a truncated splice 
variant, lacking the C-terminal end of the full-length FosB protein, which is a member of 
the Fos family proteins including c-fos, FosB. ΔFosB is a product of the fosB gene and 
slowly accumulates in the cell over repeated stimulation as compared to the rapid 
induction and decline of c-fos and FosB (Nestler, 2008). The possible mechanism 
underlying the high stability property of ΔFosB may be due to the lack of the C-terminus 
that may be involved in the destabilization of the full-length protein (Carle, et al., 2007). 
All Fos family proteins are transcription factors in which they bind with other proteins to 
deoxyribonucleic acid (DNA) and control the transcription of genetic information from 
DNA to messenger RNA (mRNA). Due to its rapid activation, c-Fos is generally used as 
biological marker of acute stimulation as compared to ΔFosB that is often used as a 
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marker of repeated stimulation because of its long half-life. However, it will be discussed 
later that ΔFosB may be more than a biological marker and may induce long-lasting 
cellular plasticity and adaptations in the brain.  
As mentioned previously, ΔFosB is encoded by the fosB gene and is detected 
within the nucleus of the neuron, currently there is no findings of ΔFosB outside the 
nucleus as compared to other transcription factors such as CREB (Damez-Werno, et al., 
2012). ΔFosB is measurable in the striatum and the suprachiasmatic nucleus within the  
hypothalamus under basal conditions (McClung, et al., 2004). However, after chronic 
stimuli exposure such as stress, drugs of abuse, antidepressants, and antipsychotics, 
ΔFosB increased expression is located in brain regions including: NAc, PFC, VTA, 
amygdala, hippocampus, dorsal striatum, locus coeruleus, and septum (McClung, et al., 
2004). Within the NAc, ΔFosB expression after chronic stimuli has been detected in 
medium spiny neurons (MSN) including dopamine D1 and D2 containing neurons 
(Grueter, et al., 2013). Therefore, ΔFosB can be induced in many different regions in the 
brain, however areas most affected after repeated stimulation seem to be areas involved 
in the dopamine pathways, however no direct link between dopamine and ΔFosB under 
basal conditions has been determined (McClung, et al., 2004).  
Although ΔFosB expression is a useful biological marker of repeated activation, 
through its possible function it may also be involved in cellular and behavioral plasticity. 
The Fos family of transcription factors preferentially dimerize with Jun family proteins 
(c-Jun, JunB, and JunD) to form the activator protein (AP-1) complex, which then binds 
to the AP-1 binding site (Hope et al., 1994). ΔFosB can bind to all Jun family members, 
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however the predominant binding partner in vivo appears to be JunD (McClung, et al., 
2004). Unlike ΔFosB, JunD can form a homodimer with itself to form the AP-1 complex 
and often does because it is a constitutively active protein and at higher concentrations as 
compared to ΔFosB (Harlan & Garcia, 1999). 
 Upon binding with the Jun family of proteins, ΔFosB appears to act as a 
transcriptional repressor with short-term stimulation and then as a transcriptional 
activator as it accumulates with chronic stimulations (McClung & Nestler, 2003).  
Similar to CREB, ΔFosB is implicated in neural plasticity, specifically synaptogenesis as 
evidenced by increased dendritic spines on D1 receptor-containing neurons in the NAc 
after repeated cocaine or sexual experiences (Pitchers et al., 2013; Vialou et al., 2012). A 
sequence of intracellular events connecting ΔFosB activation with increased dendritic 
spines has not yet been determined. However, plausible mechanisms include the 
involvement of other transcription factors or proteins important in cellular growth and 
plasticity, such as GluR2, nuclear factor kappa B (NFκB), or cyclin-dependent kinase 5 
(Cdk5) (Nestler, 2008). There is limited research on the mechanisms required for ΔFosB 
expression in the NAc after repeated stimuli. After repeated cocaine administration, 
CREB and serum response factor (SRF) are both needed for ΔFosB in mice (Vialou et al., 
2012); however, there is no research on the mechanism required for ΔFosB expression 
after repeated D2-like agonist or antagonist treatment is currently unknown. 
As mentioned previously, ΔFosB is an important protein because it is a biological 
marker of long-term stimulation; it is also a useful transcription factor and may be an 
underlying mechanism for persistant behavioral changes related to drug abuse. However, 
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little is known about ΔFosB and antipsychotics.  Repeated typical antipsychotic treatment 
significantly increases ΔFosB labeling in both dorsal and ventral areas of the striatum 
(Rodriguez, Garcia, Nakabeppu, & Pickel, 2001). However, repeated atypical 
antipsychotic treatment increases ΔFosB labeling only in ventral striatum (Vahid-Ansari 
& Robertson, 1996). The effect of D2-like agonist treatment, acute or repeated, on ΔFosB 
is currently unknown. Furthermore, the majority of studies examining the characteristic, 
induction, or effects of ΔFosB are done in reference to drugs of abuse, typically with 
cocaine. This emphasizes a gap in the literaure that could be benificial to schizophrenia 
research. 
Repeated D2-like receptor agonist treatment alleviates prior PPI deficits, termed a 
PPI recovery (Culm & Hammer, 2004). The underlying mechanisms for PPI recovery 
involve phosphorylatoin of CREB in the NAc (Berger et al., 2011). However, this does 
not fully explain the long-lasting properties of PPI recovery. The long lasting 
characteristics and involvement in neural plasticity suggests ΔFosB may be involved in 
the presistant behavioral change. If ΔFosB is involved in the mechanisms of PPI 
recovery, it would be benificial to determine the process through which it is induced. 
Currently, there is limited research on the pathway(s) responsible for its expression.  
Summary  
The goal of this project is to determine the intracellular signaling mechanism by 
which NAc neurons cause persistent recovery of sensorimotor gating after repeated D2-
like agonist treatment in rats. This intracellular mechanism could provide future 
therapeutic targets to treat cognitive symptoms and possibly avoid side effects. To test the 
therapeutic relevance of repeated D2-like receptor agonist treatment, we will compare 
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previous behavioral and intracellular findings with a novel antipsychotic that has a 
similar pharmacological profile. Results from these findings will give us a more complete 
picture of the dynamic properties of neurons vital to schizophrenia behavior and 
treatment.  
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Chapter 2 
REPEATED QUINPIROLE TREATMENT INDUCES RECOVERY OF PREPULSE 
INHIBITION AND ΔFOSB LABELING IN NUCLEUS ACCUMBENS IN RATS 
Abstract 
Prepulse Inhibition of the acoustic startle response (PPI) is an operational 
measurement of sensorimotor gating, which is disrupted in patients with schizophrenia. 
Previous research determined that acute administration of dopamine D2 -like receptor 
agonist, quinpirole, disrupts PPI while repeated treatment alleviated prior PPI deficits, 
termed a PPI recovery. Also, cyclic adenosine monophosphate (cAMP) responsive 
element binding (CREB) protein phosphorylation in the nucleus accumbens (NAc), as is 
also observed after antipsychotic administration. We examined the effect of repeated 
treatment with quinpirole (0.1 mg/kg,) on PPI at 1, 14, and 28 days in adult Sprague 
Dawley rats. PPI was significantly reduced by acute quinpirole, but PPI deficits were 
gradually alleviated after 28 days of treatment. Furthermore, we investigated the role of 
the long-lasting transcription factor, ΔFosB as a possible catalyst for these behavioral 
changes. Stereological analysis of immunohistolochemical labeling revealed a significant 
increase of ΔFosB expression in the NAc core and shell of rats repeatedly treated with 
quinpirole as compared to vehicle-treated subjects. By contrast, ΔFosB labeling in the 
dorsal striatum did not differ significantly. These behavioral data replicate previous 
findings from our laboratory, while increased ΔFosB labeling localized to the NAc 
suggests the presence of long-term intercellular changes that could underlie PPI recovery 
after repeated treatment with D2 -like agonists.   
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Introduction   
Sensorimotor gating deficits affect the ability to properly process information leading 
to cognitive deficits and thought disorder in patients with schizophrenia. This can be 
measured using prepulse inhibition of the acoustic startle response (PPI) in both humans 
and rats. PPI measures the ability of the subject to inhibit the startle response to a pulse 
stimulus in the presence of barely detectable prepulse stimulus up to 500 msec earlier. 
Normally, a complex brain circuit transfers information after the prepulse to inhibit the 
brain stem startle response to the subsequent pulse stimulus. This circuit is disrupted in 
patients with schizophrenia and schizotypic individuals resulting in PPI deficit 
(Swerdlow et al., 2006). Animal models of PPI deficits through ablations or 
pharmacological manipulations have illuminated brain areas and neurotransmitter 
systems involved in PPI.  
Dopamine induces PPI deficits in rats via D2-like receptors in the nucleus accumbens 
(NAc) (Wan & Swerdlow, 1993). Rats display PPI deficits after an acute systematic 
administration of direct and indirect dopamine agonists, apomorphine and cocaine 
(Geyer, Krebs-Thomson, Braff, & Swerdlow, 2001) and specific D2-like agonists, 
ropinirole and quinpirole (Swerdlow & Geyer, 1998). Specifically, PPI deficits are 
observed after an acute direct infusion of D2-like agonists into the nucleus accumbens 
(NAc) (Wan & Swerdlow, 1993). In contrast to acute treatment, repeated treatment with 
indirect dopamine agonist, cocaine (Byrnes & Hammer, 2000) and direct dopamine 
agonists, quinpirole and ropinirole (Culm & Hammer, 2004) alleviate prior PPI deficits, 
which we term PPI recovery. PPI recovery is observable after repeated ropinirole 
treatment and 28 days later an acute ropinirole challenge continues to have no effect on 
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PPI (Berger et al., 2011). Mechanisms underlying this long lasting behavioral effect after 
repeated D2-like agonists treatment is not well characterized because most 
pharmacological studies are done acutely.  
Acute stimulation of D2-like receptors in the NAc reduces adenylate cyclase due 
to Gi/Go protein coupling, which in turn decreases cyclic adenosine monophosphate 
(cAMP) activity (Gilman, 1987). However, repeated stimulation of these D2-like 
receptors in the NAc after repeated quinpirole treatment increases adenylate cylcase as 
evidenced by a transient increase of cAMP-dependent protein kinase (PKA) activity and 
phosphorylation of cyclic adenosine monophosphate (cAMP) response element-binding 
(CREB) in the NAc (Culm & Hammer, 2004). Furthermore, expression of a dominant 
negative mutant CREB (mCREB), which inhibits phosphorylation of CREB, in the NAc, 
prevented PPI recovery (Berger et al., 2011). These findings suggest that the possible 
heterologous sensitization of these D2-like receptors is critical for PPI recovery. 
However, it is unknown how these transient cellular changes listed above are involved in 
the previously observed long-lasting PPI recovery 28 days after drug treatment. 
Therefore, we hypothesize that long lasting cellular changes may be involved in PPI 
recovery after repeated D2-like agonist treatment.  
ΔFosB is a truncated splice variant of FosB protein, which is a member of the Fos 
family proteins. ΔFosB heterodimerizes with the Jun family of proteins to form the 
activator protein-1 (AP-1) complexes that bind to the AP-1 binding site in order to 
regulate transcription (Hope et al., 1994). Fos proteins are observed rapidly in the NAc 
after acute administration of addictive drugs, such as cocaine, amphetamines, and 
nicotine (Nestler et al., 2001). ΔFosB is an effective marker for long-term use and 
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withdrawal of addictive drugs because it remains present several weeks after the last drug 
administration (Nestler et al., 2001). Repeated treamtent with typical antipsychotic 
haloperidol, D2 receptor antagonist, significantly increases ΔFosB labeling in both dorsal 
and ventral areas of the striatum (Rodriguez et al., 2001). However, repeated atypical 
antipsychotic clozapine treatment increased ΔFosB labeling in ventral areas of the 
striatum (Vahid-Ansari & Robertson, 1996). ΔFosB labeling is an excellent marker for 
neuronal activation that has not been examined after repeated D2 -like agonist treatment.  
This study examined the effects of repeated D2 -like agonist, quinpirole, on ΔFosB 
expression in the NAc as a possible underlying mechanism of PPI recovery. We 
hypothesize that repeated quinpirole treatment would cause rats to exhibit PPI recovery 
as observed in previous studies (Culm & Hammer, 2004). Furthermore, we believe that 
repeated quinpirole treatment will increase ΔFosB expression in the NAc, which may be 
involved in the underlying mechanism of long-lasting PPI recovery.  
Materials and Methods 
Animals and Drug Treatment   
Animals were provided with food and water ad libitum while housed in a climate-
controlled facility with 12-hour reverse light/dark cycles (lights off at 9:00 AM). All 
experiments were approved by the Arizona State University and University of Arizona 
Institutional Animal Care and Use Committee, and were conducted in accordance with 
the National Institutes of Health Guide for the Care and Use of Laboratory Animals. 
Male Sprague-Dawley rats (Charles River Laboratories, Hollister, CA) weighing 250-
300g upon arrival were housed three to a cage. Animals were allowed to acclimate to the 
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laboratory 7 days prior to handling.  During this acclimation, animals were habituated to 
handling and subcutaneous (SC) saline injection.  
 (-) Quinpirole hydrochloride (Sigma, St. Louis, MO) was dissolved in sterile 
saline (0.9%). Starting after PPI baseline testing, animals were treated once daily for 28 
consecutive days with quinpirole (0.1 mg/kg, SC) or 0.9% saline vehicle (1.0 ml/kg).  
Prepulse Inhibition Testing 
After acclimation to the laboratory, animals were placed into a Startle Monitor 
Behavioral Testing chamber (Kinder Scientific, Poway, CA) with 70dB ambient noise for 
5 min each day for 2 days prior to baseline testing. Treatment groups were normalized by 
the mean acoustic startle response observed on two days of baseline testing. After 
baseline testing, animals were tested on 1, 14, and 28 day of treatment.  
 PPI startle response was determined using the Startle Monitor behavioral testing 
system. All PPI testing was conducted during the dark phase (900 –1300 h). Each animal 
was placed in a PPI chamber and exposed to 70 dB ambient noise for 5 min, followed by 
a PPI baseline or test session. A PPI baseline session consisted of four consecutive pulse 
trials (120 dB, 40-msec pulses), a randomized presentation of 8 no stimulation, 16 pulse, 
and 15 prepulse (10 each of 73, 76, and 82 dB, 20 msec prepulses, followed 100 msec 
later by a pulse) trials, and ending with four pulse trials. A PPI test session consisted of 
four consecutive pulse trials (120 dB, 40-msec pulses), a randomized presentation of 10 
no stimulation, 16 pulse, and 30 prepulse (10 each of 73, 76, and 82 dB, 20 msec 
prepulses, followed 100 msec later by a pulse) trials, and ending with four pulse trials. 
The inter-trial interval averaged 15 sec (range: 8–22 sec). Percent PPI was calculated as: 
100-[(mean prepulse response/mean pulse response) × 100]. 
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Perfusion and Tissue Preparation  
 Animals were euthanized 10 days after last drug treatment to ensure that residual 
quinpirole had metabolized and that immunohistochemical labeling would reflect the 
presence of persistent ΔFosB protein. ΔFosB labeling is detectable only 4-12 after 
induction (McClung & Nestler, 2003). Animals were anesthetized with an overdose of 
sodium pentobarbital (100 mg/kg) and perfused transcardially with 10 mL of 10% 
heparin in 0.1M phosphate-buffered saline (pH 7.4) followed by 225 mL of 4% 
paraformaldehyde in 0.1M phosphate buffer (pH 7.4). Brains were removed, post-fixed 
for 2h in the same fixative at 4°C. Coronal sections (20µm) were taken on a sliding 
microtome from the level of 2.7-0.7 mm anterior to bregma for the NAc (Paxinos & 
Watson, 2007). Sections were collected in 0.1M phosphate buffer (pH 7.4 at 4°C), 
mounted onto glass slide (Superfrost Plus; Fisher; Waltham, MA), dried and stored at      
-35°C until the time of processing.  
FosB/ΔFosB Immunohistochemistry  
Slides were washed three times in 0.05 M potassium phosphate-buffered saline 
(KPBS, pH 7.4), and incubated in 5% normal goat serum/0.05 m KPBS/0.4% Triton X 
for 60 min at room temperature. To determine ΔFosB labeling, primary antibody raised 
against the N-terminal region of FosB (SC-48; Santa Cruz Biotechnology, Santa Cruz, 
California) was used at a dilution of 1: 5,000 in 5% normal goat serum/0.05M 
KPBS/0.4% Triton X. This antibody recognizes 32–37 kDa proteins corresponding to the 
molecular weight of ΔFosB-like proteins and full-length FosB (Perrotti et al., 2004). 
Following incubation for 48 h at 4°C, sections were washed three times in 0.05M 
KPBS and processed using avidin–biotin–peroxidase (Vectastain ABC Elite kit, Vector 
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Laboratories, Burlingame, California). Sections were developed with 3, 3’-
diaminobenzidine (DAB) for 5 min, dehydrated and coverslipped at room temperature. 
Control procedures included preabsorption of the primary antibody using FosB peptide, 
and conducting these procedures in the absence of the primary antibody. There was no 
detectable labeling after any of the procedures (not shown). 
 Immunohistochemical Analysis 
Tissue sections were examined for the presence of a dark grey reaction product. 
Labeled profiles were obtained from 3-4 sections from each rat. Selected areas of 400 
µm2   within the NAc core, shell, and caudate putamen were captured and digitized using 
a color digital video camera interfaced to a Zeiss Axioskop microscope with a 20X 
objective. Labeled profiles within the areas of interest were determined using 
StereoInvestigator (MicroBrightField Biosciences, Inc., Willston, VT, USA).  A 
systematic random sampling approach using a stereological grid, consisting of 16 equal 
counting frames (100 X 100µm each) ensured randomization of identification within the 
area. A profile was considered labeled if its pixel luminance was more than two standard 
deviations different from the background luminance as calculated by Stereo Investigator 
software. The average labeled profiles in an area were determined for each animal and 
these data were transformed to express the number of labeled profiles per mm2.  
Statistical Analysis 
Startle response (120dB) and response in the presence of ambient noise alone, 
were analyzed using a repeated measures analysis of variance (ANOVA). Percent PPI 
(mean ± SEM) are mean values collapsed across three prepulse intensities. PPI responses 
within a single day were analyzed using a student’s T-test. PPI responses across multiple 
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days were analyzed using two-way repeated-measures ANOVA with day of testing as 
within subject factor and drug treatment as between subject factor. ΔFosB labeled 
profiles were analyzed using two-way repeated measures ANOVA with brain area as 
within subject factor and drug treatment as between subject factor. Post-hoc comparisons 
were made using Fisher’s least squares difference (LSD). All data are presented as mean 
± SEM and PPI responses are presented collapsed across prepulses 3, 6, and 12 dB above 
ambient noise level (70dB).  
Results 
PPI Recovery Following Repeated Quinpirole  
This experiment demonstrates that acute treatment with quinpirole significantly, 
disrupted PPI, as previously observed (Figure 2) (Berger et al., 2011; Culm & Hammer, 
2004). Specifically, quinpirole (0.1 mg/kg) reduced PPI by 49% compared to vehicle 
treatment on day 1. Rats did not display PPI deficits after repeated quinpirole treatment 
when compared to controls on day 28 of testing. Furthermore, repeated quinpirole 
treatment significant increased in PPI performance from day1 to day 28 of testing; 
quinpirole (0.1 mg/kg) increased PPI performance by 41% from Day 1 to Day 28. There 
was also no significant effect of drug treatment on startle (120 dB) or no stimulus (70 dB) 
ambient noise response on day 28 of PPI testing.  
ΔFosB Expression in the NAc Following Repeated Quinpirole  
Modified stereological analysis revealed a significant increase of ΔFosB positive 
cells 10 days after repeated quinpirole treatment (Figure 3). This effect was visible in 
both the NAc core and shell, but not in the CPu. Labeling density increased by 241.72% 
in the NAc core and by 158.03% in the shell after repeated quinpirole treatment. There 
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was also a significant increase in total labeled cells in the NAc core and shell as 
compared to the CPu.  
Discussion  
Recovery of Sensorimotor Gating Deficits after Repeated D2-like Agonist  
Acute administration of D2 -like receptor agonist in the NAc disrupts PPI, a model 
of sensorimotor gating deficits (Wan & Swerdlow, 1993). Antipsychotics given prior to 
acute D2-like receptor agonist challenge can alleviate deficits and are believed to relate to 
the clinical efficacy of the drug (Swerdlow et al., 1994). Interestingly, repeated D2-like 
agonist treatment can also alleviate PPI deficits (Berger et al., 2011; Culm & Hammer, 
2004; Culm et al., 2004). In the current study, acute quinpirole induced PPI deficits and 
repeated quinpirole treatment alleviated prior deficits, termed a PPI recovery. This 
supports previous observations of PPI recovery after repeated D2-like agonist treatment 
(Berger et al., 2011; Culm & Hammer, 2004; Culm et al., 2004). There are no other 
studies examining the effect of repeated D2-like agonist treatment on PPI. Repeated D2 
antagonist antipsychotics alleviate phencyclidine (PCP) induce PPI deficits after 6 days 
of treatment, however this was only observed after atypical antipsychotic treatment (Li, 
He, & Volf, 2011). This suggests repeated D2-like agonist treatment may have some 
therapeutic relevance.  
Repeated D2-like Agonist Treatment Induces ΔFosB in NAc  
PPI recovery is observable 28 days after treatment (Berger et al., 2011). This 
suggests a sustainable intracellular component may be involved in this persistent 
behavioral change. Previously, repeated D2-like agonist treatment increased PKA activity 
and CREB phosphorylation, however CREB phosphorylation was not observable 28 days 
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after repeated treatment (Berger et al., 2011). Therefore, we hypothesized that due to its 
long half-life and association with synaptic plasticity that ΔFosB may be involved in 
preserving PPI recovery. In the current study, we found a significant increase in ΔFosB in 
the NAc core and shell 10 days after repeated D2-like agonist treatment. We believe this 
induction of ΔFosB may be involved in long lasting PPI recovery.  
ΔFosB expression in the striatum is observed after multiple types of repeated 
stimuli, such as chronic cocaine administration, stress exposure, and antipsychotic 
treatment. ΔFosB induction after these different stimuli is believed to affect different 
resulting behaviors, however all the resulting behaviors are persistent and may involve 
neural plasticity. ΔFosB expression after chronic cocaine increases drug reward, which 
may be a factor in the propensity for relapse (Nestler et al., 2001). Repeated stress 
exposure induces ΔFosB and is believed to be involved in anti-depressant like behaviors 
or resiliency (Perrotti et al., 2004). Repeated typical antipsychotic increased ΔFosB and is 
believed to be responsible to tardive-dyskinesia-like behaviors in rats (Rodriguez et al., 
2001). It should be noted the administration of antipsychotic was for 6 months via oral 
administration, which may be different from systemic administration. These studies 
suggest that ΔFosB is induced after repeated stimuli and results in long-lasting behavioral 
change.  
The exact mechanism that ΔFosB produces persistent behavioral change is 
unknown, but is believed to involved neural plasticity. After chronic cocaine and sexual 
encounters, increased dendritic spines and ΔFosB were observed in the NAc (Pitchers et 
al., 2013). These neurons are believed to express D1 receptors because of their 
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involvement in the reward pathway (Nestler, 2008). There are currently no studies 
examining the effect ΔFosB on cellular plasticity after repeated D2-like agonist treatment, 
however repeated exposure to stress increases ΔFosB in both D1 and D2 containing 
neurons (Vialou et al., 2012). Although we do not know what cells are expressing ΔFosB 
after repeated D2-like agonist treatment, we can assume they are neurons expressing D2-
like receptors because PPI regulation is modulated by NAc indirect pathway, which 
contains neurons expressing D2-receptors (Wan & Swerdlow, 1993). Therefore, if ΔFosB 
is found in D2-containing neurons and cells that express ΔFosB also have increased 
dendritic spines, we can hypothesize that repeated D2-like agonist treatment is inducing 
ΔFosB and increased dendritic spines resulting in persistent PPI recovery.  
Future studies will need to be completed to determine the type of cell that 
regulates PPI recovery and examine if ΔFosB is affecting the cellular structure or 
function of the cell. It will also need to be determined the extent to which ΔFosB is 
involved in the preservation of PPI recovery after drug treatment. These studies elucidate 
a transcription fact that has been implicated in long lasting behavioral changes and may 
sustain PPI recovery. This study combined with previous findings of intracellular 
activation after repeated D2-like agonist treatment has determined a mechanism for the 
alleviation of a clinically relevant behavior and may have future potential therapeutic 
relevance. 
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Chapter 3 
ΔFOSB AND CYCLIC ADENOSINE MONOPHOSPHATE RESPONSE ELEMENT 
BINDING PROTEIN PHOSPHORYLATION IN NUCLEUS ACCUMBENS 
UNDERLIES RECOVERY OF SENSORIMOTOR GATING DEFICITS FOLLOWING 
REPEATED D2-LIKE AGONIST TREATMENT IN RATS 
Abstract  
Prepulse Inhibition (PPI) is a cross-species operational measurement of 
sensorimotor gating. PPI deficits are observed in patients with schizophrenia and after 
acute dopamine (DA) D2-like dopamine receptor agonist in rats. In contrast, repeated 
treatment with D2-like receptor agonists alleviates prior PPI deficits, termed a PPI 
recovery. We have previously found increases in cyclic adenosine monophosphate 
(cAMP)-response element binding protein (CREB) phosphorylation immediately after 
repeated D2-like agonist treatment and ΔFosB 10 days after treatment in the nucleus 
accumbens (NAc) of rats. This study examined if phosphorylation of CREB is required 
for ΔFosB expression and if ΔFosB transcription in the NAc is necessary for persistent 
PPI recovery after repeated D2-like receptor agonist ropinirole. In the first study, adeno-
associated virus (AAV)-mediated dominant negative mutant CREB (mCREB) prevented 
PPI recovery and suppressed repeated ropinirole-induced ΔFosB expression in the NAc. 
In the second study, AAV-induced overexpression of dominant negative ΔJunD, 
antagonist of ΔFosB, in the NAc prevented PPI recovery. The suppression of repeated 
ropinirole-induced ΔFosB expression by mCREB suggests phosphorylation of CREB is 
necessary for ΔFosB expression after repeated D2-like agonist treatment. The attenuation 
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of PPI recovery after ΔJunD infusion into the NAc after repeated D2-like receptor agonist 
treatment suggests ΔFosB is necessary for PPI recovery. These results suggest CREB 
phosphorylation and ΔFosB are involved in an underlying intracellular mechanism 
preserving PPI recovery after repeated D2-like agonist treatment. This underlying 
intracellular mechanism of long-lasting PPI recovery may be involved in sensorimotor 
gating deficits, which contribute to cognitive symptoms in patients with schizophrenia. 
Therefore, repeated D2-like agonist function may elucidate factors that contribute to the 
alleviation of cognitive deficits of schizophrenia.  
Introduction  
Patients with schizophrenia have difficulty processing information when 
distracting stimuli are presented in close and rapid succession, termed ‘sensory flooding’ 
(Braff & Saccuzzo, 1985). Sensorimotor gating prevents ‘sensory flooding’ by regulating 
or inhibiting the transmission of sensory information to a motor system (Braff & Geyer, 
1990). Prepulse inhibition of the acoustic startle response (PPI) is a quantifiable, valid, 
and reliable response that can be measured across species to detect sensorimotor gating 
deficits (Geyer et al., 2001). PPI is the reduction in startle response to an intense stimulus 
or “pulse” when preceded, up to 500 ms, by a weaker stimulus or “prepulse”. This 
neurological phenomenon involves forebrain regulation of inhibition on the brain stem 
startle response. Specifically, the nucleus accumbens (NAc) is an integral brain area 
connecting forebrain and limbic structures that modulate PPI (Swerdlow, Braff, & Geyer, 
1990), and acute local infusion of D2-like agonists produce PPI disruptions (Wan & 
Swerdlow, 1993). 
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Dopamine acting on D2-like, D2 and D3, G protein-coupled receptors in the NAc 
can disrupt PPI in rats (Wan & Swerdlow, 1993). For example, PPI disruptions are 
observed after acute systemic treatment (Martinez, Ellison, Geyer, & Swerdlow, 1999) or 
NAc infusion (Wan & Swerdlow, 1993) with D2-like receptor agonist. In contrast to 
acute treatment, repeated treatment with indirect dopamine agonist result in an attenuated 
PPI disruption in rats (Byrnes & Hammer, 2000; Feifel, Priebe, Johnstone-Miller, & 
Morgan, 2002). Repeated treatment with more specific D2-like agonists, quinpirole or 
ropinirole, completely alleviate previous PPI deficits, termed a PPI recovery (Berger et 
al., 2011; Culm & Hammer, 2004). Furthermore, this recovery after repeated treatment is 
long-lasting as rats continue to display PPI recovery four weeks after treatment (Berger et 
al., 2011). 
Repeated D2-like receptor stimulation produces heterologous sensitization of 
cyclic adenosine monophosphate (cAMP) signaling, as compared to a reduction of cAMP 
after acute D2-like receptor stimulation (Watts & Neve, 2005). Although the underlying 
mechanism of this sensitization is not well understood, it can affect down stream targets 
to induce intracellular changes. We have found increases in cAMP-dependent protein 
kinase (PKA) activity and phosphorylation of cAMP response element binding protein 
(CREB) after repeated D2-like agonist treatment (Culm et al., 2004). Furthermore, we 
have determined that phosphorylation of CREB is necessary for PPI recovery (Berger et 
al., 2011). Increases in PKA activity and phosphorylation of CREB were detected 
immediately after repeated D2-like agonist treatment and were not detected four weeks 
after treatment when PPI recovery is still observable. ΔFosB, a stable truncated splice 
variant of FosB protein, was increased after repeated D2-like agonist treatment and may 
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underlie the long-lasting characteristic of PPI recovery. ΔFosB and CREB are both 
transcription factors that have been implicated in behavioral plasticity after long-term 
drug use (Nestler, Kelz, & Chen, 1999; Newton et al., 2002). However, the direct 
connection between phosphorylation of CREB and ΔFosB expression after repeated D2-
like agonist treatment has never been examined.  
 The aim of this study is to determine if CREB phosphorylation is necessary for 
ΔFosB expression in the NAc after repeated D2-like agonist treatment and if ΔFosB is 
necessary for persistent PPI recovery. We hypothesize that bilateral overexpression of 
dominant negative mutant CREB (mCREB) in the NAc, blocking phosphorylation of 
CREB, will suppress ΔFosB in the NAc following repeated ropinirole treatment. We also 
hypothesize that bilateral overexpression of dominant negative ΔJunD, ΔFosB antagonist, 
will prevent PPI recovery after repeated D2-like receptor agonist treatment.   
Methods and Materials  
Animals and Drug Treatment 
For all the following experiments, animals were housed under a 12:12 h reverse 
light-dark cycle and given ad libitum access to water and food. Rats were allowed to 
acclimate for 7 days to the laboratory before handling and habituation to the behavioral 
testing chambers. All experiments were approved by the Arizona State University and the 
University of Arizona Institutional Animal Care and Use Committees and were 
conducted in accordance with the Guide for the care and Use of Laboratory Animals. 
Adult male Sprague-Dawley rats (Charles River Laboratories, Hollister, 
California) weighing 260-325 g were habituated to handling and subcutaneous (SC) 
saline injection and placed into a Startle Monitor behavior testing chamber (Kinder 
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Scientific, Poway, California) with 70 dB ambient noise for 5 min daily for 2 days before 
baseline testing. Baseline PPI was assessed as described later starting 10 min after 0.9% 
sterile saline vehicle injection (1.0 mL/kg, SC) on 2 consecutive days to ensure a reliable 
mean value. Treatment groups were normalized according to the mean PPI observed 
during the baseline testing.  
Ropinirole hydrochloride (HCl), obtained from National Institute of Mental 
Health's (NIMH) Chemical Synthesis and Drug Supply Program, was dissolved in a 
vehicle of saline and administered SC. Vehicle controls were 0.9% sterile saline. 
Injections took place in home cages.  
Prepulse Inhibition Testing  
All PPI testing was conducted during the dark phase (900 –1300 h). Each animal 
was placed in a PPI chamber and exposed to 70 dB ambient noise for 5 min, followed by 
a PPI baseline or test session. A PPI baseline session consisted of four consecutive pulse 
trials (120 dB, 40-msec pulses), a randomized presentation of 8 no stimulation, 16 pulse, 
and 15 prepulse (10 each of 73, 76, and 82 dB, 20 msec prepulses, followed 100 msec 
later by a pulse) trials, and ending with four pulse trials. A PPI test session consisted of 
four consecutive pulse trials (120 dB, 40-msec pulses), a randomized presentation of 10 
no stimulation, 16 pulse, and 30 prepulse (10 each of 73, 76, and 82 dB, 20 msec 
prepulses, followed 100 msec later by a pulse) trials, and ending with four pulse trials. 
The intertrial interval averaged 15 sec (range: 8–22 sec). Percent PPI was calculated as: 
100-[(mean prepulse response/mean pulse response) × 100].  
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AAV Vector Construction and Stereotaxic Injections  
 Adeno-associated virus (AAV) vectors were produced using Stratagene’s helper-
free system to add an eGFP tag to the N-terminus of mCREB and ΔJunD as described 
previously (Wallace et al., 2009; Winstanley et al., 2007).  
 ΔJunD-eGFP and mCREB-eGFP fusion proteins were created by adding an eGFP 
tag to the N terminus of ΔJunD and mCREB. Previous studies have indicated that tagging 
the N terminus of CREB does not interfere with its functional activity (Chao et al., 2002). 
ΔJunD-eGFP and mCREB-eGFP constructs with a CMV promoter were inserted into the 
pAAV-MCS plasmid and packaged according to the manufacturer’s instructions. For 
purification, packaging cells were centrifuged at 1500 x g and re-suspended in 8 ml. Cells 
were subjected to 2 freeze-thaw cycles, and contaminating DNA and RNA was digested 
with 50 U/ml Benzonase. Lysate was subjected to ultracentrifugation through an 
iodixanol gradient at 350,000 x g for 120 min at 4°C. The 40% iodixanol layer was 
removed and placed in a Biomax 100k NMWL filter column for buffer exchange. The 
virus was rinsed twice with PBS and concentrated to 100 µl; the resulting titer was 
approximately 1011 IU/ml.  
 Rats were anesthetized and placed into a stereotaxic frame, and a microsyringe 
(Hamilton; Reno, Nevada) was lowered into the NAc at the following coordinates: +1.2 
mm anterior to bregma, ±1.3 mm lateral, and 7.1 mm from the pial surface.  The bilateral 
intracranial infusion of AAV was infused bilaterally at a rate of 0.1 µl/min for 10 min on 
each side, after which the needle remained in place for 10 min. Rats were allowed 3 
weeks for recovery and adequate expression of ΔJunD or mCREB before drug treatment.  
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Experiment 1 Procedure   
 Following habituation and normalization of groups, rats under-went stereotaxic 
surgery for AAV vector-mediating gene transfer of mCREB, in which Ser133 is replaced 
with alanine to prevent phosphorylation, co-expressed with enhanced green fluorescent 
protein (eGFP) or eGFP alone bilaterally in the NAc. Three weeks after stereotaxic 
surgery, rats received ropinirole HCl (0.0 or 0.1 m/kg) (NIMH Chemical Synthesis and 
Drug Supply Program) in 0.9% sterile saline. PPI was assessed on the first and last day of 
drug administration as described earlier.   
Experiment 2 Procedure  
 Following habituation and normalization of groups, rats under-went stereotaxic 
surgery for AAV vector-mediating gene transfer of ΔJunD, a truncated mutant of the 
JunD protein that is devoid of a transactivational domain and thus functions as a 
dominant negative antagonist of activator protein-1 (AP-1) mediated transcription, 
coexpressed with eGFP or eGFP alone bilaterally in the NAc. Three weeks after 
stereotaxic surgery, rats received ropinirole HCl (NIMH Chemical Synthesis and Drug 
Supply Program) in 0.9% sterile saline. PPI was assessed on the first and last day of drug 
administration as described earlier.  
Immunohistochemistry    
Ten days after the last drug challenge, rats were anesthetized and perfused with 
heparinized saline followed by 4% buffered paraformaldehyde. Brains were post-fixed in 
the same fixative for 2 h at 4° C then placed in graded sucrose solutions in phosphate 
buffered saline (PBS) overnight. Striatal brain sections (20 µm) were mounted on slides. 
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The location of eGFP-labeled neurons were documented in each brain (Neurolucida; 
MBF Biosciences) to determine the infusion site and the spread of viral infusion.  
After eGFP confirmation, slides were washed three times in 0.05 M potassium 
phosphate-buffered saline (KPBS, pH 7.4), and incubated in 5% normal goat 
serum/0.05 m KPBS/0.4% Triton X for 60 min at room temperature.  
To determine ΔFosB labeling in experiment 1, primary antibody raised against the 
N-terminal region of FosB (SC-48; Santa Cruz Biotechnology, Santa Cruz, California) 
was used at a dilution of 1: 10,000 in 5% normal goat serum/0.05 m KPBS/0.4% Triton 
X. This antibody recognizes 32–37 kDa proteins corresponding to the molecular weight 
of ΔFosB-like proteins and full-length FosB (Perrotti et al., 2004).  
To determine CREB labeling in experiment 1, primary antibody raised against the 
amino terminus, not the Ser133, of CREB (48H2; Cell Signaling Technology, Inc., 
Danvers, Massachusetts) was used at a dilution of 1: 12,000 in 5% normal goat 
serum/0.05 m KPBS/0.4% Triton X. This antibody does not recognize the Ser133, 
therefore it will detect both endogenous CREB and mCREB (Berger et al., 2011).    
To determine JunD labeling in experiment 2, primary antibody raised against the 
C-terminus region of JunD (SC-74; Santa Cruz Biotechnology, Santa Cruz, California) 
was used at the dilution of 1:20,000 in 5% normal goat serum/0.05 m KPBS/0.4% Triton 
X. This antibody recognizes the C-terminus of the JunD protein that is shared with the 
truncated ΔJunD protein (Peakman et al., 2003; Zachariou et al., 2006). 
Following incubation for 48 h at 4°C, sections were washed three times in 0.05M 
KPBS and processed using avidin–biotin–peroxidase (Vectastain ABC Elite kit, Vector 
Laboratories, Burlingame, California). Sections were developed with 3, 3’-
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diaminobenzidine (DAB) for 5 min, dehydrated and coverslipped at room temperature. 
Control procedures included pre-absorption of the primary antibody using FosB peptide, 
and conducting these procedures in the absence of the primary antibody. There was no 
detectable labeling after any of the procedures (not shown). 
Fluorescent immunohistochemistry  
 Sections were washed in 0.05M potassium phosphate-buffered saline (KPBS), 
then blocked for 1h in 5% normal goat serum, 0.4% Triton X-100 in 0.05M KBPS. 
Sections were incubated with a primary antibody of mouse anti-FosB/ΔFosB (SC-48; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a dilution of 1:500 in 5% normal 
goat serum/0.05M KPBS/ 0.4% Triton X for 48 hours in 4°C. Sections were washed three 
times for 5 min in 0.05M KPBS and then incubated with goat anti-rabbit IgG and Alexa 
Fluor 546 goat anti-mouse IgG (Invitrogen, NY, USA) at a dilution of 1:1000 in 5% 
normal goat serum/0.05M KPBS/ 0.4%Triton X for 1 hr. Slides were cover slipped with 
Vectashield hard set mounting medium with 4’,6-Diamido-2-Phenylindole, 
Dihydrochloride (DAPI; Vector Laboratories, Burlingame, CA, USA).  Appropriate 
positive and negative controls were used for both primary and secondary antibodies (not 
shown).  
Immunohistochemical Analysis 
Tissue sections were examined for the presence of a dark grey reaction product. 
Labeled profiles were obtained from 3-4 sections from each rat. Selected areas of 400 
µm2   within the NAc core, shell, and caudate putamen were captured and digitized using 
a color digital video camera interfaced to a Zeiss Axioskop microscope with a 20X 
objective. Labeled profiles within the areas of interest were determined using 
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StereoInvestigator (MicroBrightField Biosciences, Inc., Willston, VT, USA).  A 
systematic random sampling approach using a stereological grid, consisting of 16 equal 
counting frames (100 X 100µm each) ensured randomization of identification within the 
area. A profile was considered labeled if its pixel luminance was more than two standard 
deviations different from the background luminance as calculated by Stereo Investigator 
software. The average labeled profiles in an area were determined for each animal and 
these data were transformed to express the number of labeled profiles per mm2. For JunD 
labeling analysis, immunohistochemical conditions were optimized to minimize detection 
of endogenous JunD, which is expressed universally in the brain.  
Statistical Analysis  
Startle response (120dB) and response in the presence of ambient noise alone, 
were analyzed using a repeated measures analysis of variance (ANOVA). Percent PPI 
(mean ± SEM) are mean values collapsed across three prepulse intensities.  PPI responses 
within a single day were analyzed using a one-way ANOVA. PPI responses across 
multiple days were analyzed using two-way repeated-measures ANOVA with day of 
testing as within subject factor and treatment (drug and virus) as between subject factor. 
Labeled profiles were analyzed using two-way repeated measures ANOVA with brain 
area as within subject factor and drug treatment as between subject factor. Post-hoc 
comparisons were made using Fisher’s least squares difference (LSD). All data are 
presented as mean ± SEM and PPI responses are presented collapsed across prepulses 3, 
6, and 12 dB above ambient noise level (70dB). 
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Results  
mCREB Prevents PPI Recovery after Repeated Ropinirole Treatment 
 Acute ropinirole challenge significantly reduced PPI as compared to acute saline 
challenge (Figure 5). After 28 days of ropinirole treatment, PPI was fully restored in rats 
expressing eGFP alone. In contrast, PPI remained disrupted after repeated ropinirole 
treatment in rats overexpressing mCREB. There was no effect of virus infusion or 
repeated ropinirole treatment on pulse (120dB) startle response (Table 2) or no stimulus 
(70dB ambient noise) response (Table 3). However, pulse (120dB) startle response over 
time; this has been observed previous (Berger et al., 2011) and was not dependent on 
repeated drug treatment.  
mCREB Prevents Repeated Ropinirole-Induced ΔFosB in the NAc 
Repeated ropinirole treatment significantly increased ΔFosB in the NAc core and 
shell in rats expressing eGFP alone (Figure 6) compared to repeated saline treated 
animals; this was previously observed (Chapter 2). In contrast, ΔFosB was not 
significantly increased after repeated ropinirole treatment in rats overexpressing mCREB 
as compared to repeated ropinirole treatment rats expressing only eGFP (Figure 7, Figure 
8). There was an unexpected increase of ΔFosB in the NAc of animals repeatedly treated 
with saline, although some co-expression with eGFP was detected, ΔFosB labeling was 
expressed throughout the NAc (Figure 9). Inter-Reliability Score, Avg = 95.67, SD = 0. 
577. There was a significant increase in total CREB labeling in rats with mCREB 
overexpression (Figure 10) as compared to rats with eGFP alone. There was also 
significantly more total ΔFosB expression in the NAc core as compared to the other areas 
of the striatum; Inter-Reliability score, Avg = 95.67, SD = 0. 577. There was no 
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significant difference in the amount of adeno-associated virus for gene transfer infused 
into the different treatment groups (Table 4).  
ΔJunD Prevents PPI Recovery After Repeated Ropinirole Treatment  
Acute ropinirole challenge significantly reduced PPI as compared to acute saline 
challenge (Figure 11). After 28 days of ropinirole treatment, PPI fully recovered in rats 
expressing eGFP alone. In contrast, PPI remained disrupted after repeated ropinirole 
treatment in rats overexpressing ΔJunD (ΔFosB antagonist). There was no effect of virus 
infusion on pulse (120dB) startle response (Table 5) or no stimulus (70dB ambient noise) 
response (Table 6). There was an effect of repeated ropinirole on no stimulus (70dB 
ambient noise) response as compared to repeated saline treated animals regardless of 
virus infusion. Pulse (120dB) startle response over time; this has been observed previous 
(Berger et al., 2011) and was not dependent on repeated drug treatment.  
ΔJunD Infusion Increased JunD in the NAc Core  
JunD labeling was significantly increased in the NAc core as compared to other 
areas of the striatum (Figure 12) in rats after ΔJunD infusion in the NAc core; intra-
reliability score, Avg = 98.5, SD = 2.12. There was no significant difference in the 
amount of AAV for gene transfer infused into the different treatment groups (Table 7).  
Discussion 
Recovery of Sensorimotor Gating Deficits after Repeated D2-like Receptor Agonist 
Treatment  
 In order to examine sensorimotor gating deficits in rodents, our laboratory and 
others have determined acute systemic administration of D2-like receptor agonist, 
ropinirole, induces PPI deficits (Berger et al., 2011; Swerdlow, Taaid, Oostwegel, 
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Randolph, & Geyer, 1998). In contrast to acute administration, repeated D2-like agonist 
treatment alleviates prior deficits (Berger et al., 2011; Culm & Hammer, 2004; Culm et 
al., 2004). In the current studies, acute ropinirole (0.1 mg/kg) challenge caused PPI 
deficits and repeated treatment alleviated the previous deficits, thus replicating our earlier 
findings. This previously observed behavioral change suggests the underlying 
mechanisms for the change may be a tolerance or adaptation in the brain after repeated 
treatments. Repeated D2-like agonist treatment failed to change in the amount of G 
protein levels or change G protein function in the NAc after repeated activation of D2-like 
receptors (Culm & Hammer, 2004), thus suggesting an intracellular mechanism may be 
regulating PPI recovery. Repeated D2-like receptor agonist ropinirole significantly 
increase CREB phosphorylation and ΔFosB supporting they theory that intracellular 
adaptations may underlie PPI recovery (Chapter 2) (Berger et al., 2011; Culm et al., 
2004). 
CREB Activation in the NAc is Necessary for PPI Recovery and ΔFosB After 
Repeated D2-like Agonist Treatment 
Previously, we observed an increase in CREB phosphorylation after repeated D2-
like agonist treatment and blocking CREB phosphorylation with a dominant negative 
mCREB virus infused into the NAc prevented PPI recovery (Berger et al., 2011; Culm et 
al., 2004). We also observed an increase in ΔFosB in the NAc after repeated D2-like 
agonist treatment (Chapter 2) that may underlie the long-lasting property of PPI recovery. 
The selective expression of CREB phosphorylation and ΔFosB in the NAc and the 
involvement of these transcription factors in behavioral plasticity led us to hypothesize 
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that the phosphorylation of CREB was required for ΔFosB in the NAc after repeated D2-
like agonist treatment.  
To determine if ΔFosB induction requires CREB phosphorylation in the NAc, we 
infused an AAV-mediated gene transfer to produce prolonged overexpression of mCREB 
in the NAc and assessed PPI and ΔFosB expression. We found that mCREB 
overexpression prevented PPI recovery, supporting prior work (Berger et al., 2011). 
Mutant CREB overexpression in the NAc also suppressed ropinirole-induced ΔFosB 
expression in the NAc. We also observed increased CREB expression, which confirmed 
the function of the mCREB virus function to manufacture mCREB thus increasing the 
amount of CREB labeled cells.  
We found an unexpected significant increase of ΔFosB in the NAc of animals that 
received mCREB virus and repeated saline treatment. The limited florescent overlay of 
eGFP, used to confirm mCREB infusion, and ΔFosB displayed some cells that contain 
co-expression, however most ΔFosB labeled cells were not in the infusion area or co-
labeled with GFP. A similar study did not find increased ΔFosB after using a viral-
mediated Cre-recombinase knock out of CREB, however only eGFP positive neurons 
were analyzed, therefore it is unknown if cells outside the infusion site expressed ΔFosB 
(Vialou et al., 2012). In order to examine the effect of repeated D2-like treatment and 
mCREB on the NAc, the current experiment did not require ΔFosB positive cells to also 
express eGFP in order to be counted. Therefore, cells may be counted that were not 
infused with the virus, future analysis will determine if only counting eGFP containing 
cells yields different results. There are two theories that may explain the unexpected 
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increase of ΔFosB. The first theory is that cells infected with mCREB may become 
dysregulated and affect other nearby medium spiny neurons (MSN) resulting in an 
elevation of ΔFosB. We believe these are MSN because this cell type comprises 
approximately 95 percent of the NAc (Meredith, 1999). Projection neurons from the NAc 
arborizing locally before projecting out of the accumbens (Meredith, Pennartz, & 
Groenewegen, 1993) and approximately 10 percent of MSN are interneurons (Meredith, 
1999), thus supporting that if a dysregulation occurred after mCREB infusion it could 
affect nearby cells in the NAc. The second theory suggests that additional chromatin 
modifications at the fosB gene are being affected by mCREB and may result in an 
increased expression of ΔFosB (Vialou et al., 2012). Future studies will test the validity 
of these theories; until then, we conclude from these results that mCREB is necessary for 
ΔFosB after repeated ropinirole treatment. Therefore, phosphorylation of CREB may not 
be necessary for ΔFosB expression, however after repeated D2-like agonist treatment 
CREB phosphorylation is necessary for ΔFosB and PPI recovery.  
CREB and ΔFosB have been implicated in behavioral plasticity after chronic 
cocaine administration (Vialou et al., 2012). Both transcription factors regulate gene 
expression, however this regulation is dependent on length of drug exposure. CREB and 
serum response factor (SRF) are necessary for ΔFosB expression in the NAc after 
repeated cocaine exposure (Vialou et al., 2012). It should be noted these behavioral 
effects after cocaine exposure generally coincide with alteration in dynorphin expression 
thus suggesting these changes are occurring in D1-like containing neurons in the NAc. 
However, PPI is regulated by D2-like receptor containing neurons and PPI recovery is 
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produced by D2-like receptor agonist treatment, suggesting D2-like receptor containing 
neurons are preferentially involved in PPI recovery. No other study has examined the 
connection between phosphorylation of CREB and ΔFosB after repeated D2-like agonist 
treatment. SRF may also be involved in ΔFosB expression after repeated D2-like agonist 
treatment, however in the current study the blockage of CREB phosphorylation 
significantly decreased ropinirole-induced ΔFosB in the NAc, suggesting CREB 
phosphorylation is necessary for ΔFosB in the NAc after repeated D2-like agonist 
treatment.  
ΔFosB Function in the NAc is Necessary for Persistent PPI recovery 
Previously, we observed PPI recovery 28 days after repeated D2-like agonist 
treatment (Berger et al., 2011). Due to the long half-life and stability of ΔFosB, we 
hypothesized it was critical for persistent PPI recovery. Previously, repeated D2-like 
agonist treatment increased ΔFosB in the NAc after repeated D2-like agonist treatment 
(Chapter 2); however, it was unknown if ΔFosB was required for long-lasting PPI 
recovery. In the current study, we determined ΔJunD overexpression blocked ΔFosB 
function and prevented PPI recovery. Overexpression of ΔJunD increased JunD 
expression in the NAc confirming the virus over expressed ΔJunD, which was detected 
with the JunD antibody.  
 ΔFosB has been associated long-term behavioral plasticity (Nestler et al., 2001). 
Within the NAc, long term ΔFosB expression leads to enhanced food and drug-
reinforcement, and voluntary wheel running (McClung & Nestler, 2008). These believed 
mechanism for these long-lasting behavioral changes include ΔFosB regulation of gene 
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expression resulting in increased synaptogenesis (McClung & Nestler, 2008; Pitchers et 
al., 2013). Although these effects are believed to be occurring in NAc D1-like receptor 
containing neurons, there is evidence of co-expression of different types of dopamine 
receptors that may be involved in PPI recovery after repeated D2-like agonist treatment 
(Pou, Mannoury la Cour, Stoddart, Millan, & Milligan, 2012). Neurons containing D2-
like receptors in the NAc may be modified via ΔFosB expression after repeated D2-like 
agonist treatments to cause PPI recovery. Further investigations will characterize these 
NAc cells that regulate PPI recovery 
 Repeated D2-like receptor agonist treatment produces PPI recovery in rats (Berger 
et al., 2011; Culm & Hammer, 2004; Culm et al., 2004). To determine the underlying 
intracellular mechanisms, we determined that CREB phosphorylation was necessary for 
PPI recovery and repeated ropinirole-induced ΔFosB expression in the NAc. ΔFosB in 
the NAc was also necessary for PPI recovery after repeated D2-like agonist treatment, 
suggesting it may be vital for the preservation of PPI recovery. Collectively, these 
findings are a causative connection between CREB phosphorylation and ΔFosB after 
repeated D2-like receptor agonists, suggesting these factors are involved in an 
intracellular underlying mechanism regulating sensorimotor gating deficits. These 
findings elucidate vital factors that control gene regulation within a specific brain region 
that is involved in a clinically relevant behavioral deficit observed in patients with 
schizophrenia.  
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Chapter 4 
REPEATED ARIPIPRAZOLE TREATMENT REVERSES QUINPIROLE-INDUCED 
PREPULSE INHIBITION DEFICITS AND INDUCES ΔFOSB IN THE RAT 
NUCLEUS ACCUMBENS 
Abstract  
 Prepulse inhibition (PPI) of the startle response is an operational measurement of 
sensorimotor gating, which is disrupted in patients with schizophrenia. Dopamine D2-
receptor partial agonist aripiprazole alleviates positive, negative, and to some degree 
cognitive symptoms of schizophrenia. Our laboratory has shown that repeated treatment 
with D2-like dopamine agonists, such as quinpirole, produces long-lasting recovery of 
PPI deficits and induces phosphorylation of cAMP response element-binding protein 
(CREB) and ΔFosB labeling in the rat nucleus accumbens (NAc). Although most 
antipsychotics act as D2-receptor antagonists, we hypothesize that the D2-receptor agonist 
efficacy of aripiprazole will produce persistent PPI recovery and induce ΔFosB labeling 
in the NAc. We examined the effect of acute aripiprazole treatment prior to a quinpirole 
challenge on PPI in male Sprague Dawley rats. Acute aripiprazole treatment significantly 
attenuated quinpirole-induced PPI deficits. We also examined the effect of repeated 
aripiprazole treatment for 28 days on PPI. Quinpirole challenge significantly reduced PPI 
prior to aripiprazole treatment, however quinpirole-induced PPI deficits were not 
observed 7 days after aripiprazole treatment. Immunohistochemical labeling and 
stereological analysis revealed a significant increase of ΔFosB expression in the striatum, 
especially NAc core, of aripiprazole treated rats as compared to vehicle-treated subjects. 
The reversal of PPI deficits by repeated treatment with quinpirole and aripiprazole 
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suggests that agonist properties of aripiprazole might underlie PPI recovery. Furthermore, 
the induction of ΔFosB in the striatum of aripiprazole treated rats indicates the presence 
of long-term intracellular activity resulting from repeated D2-receptor agonist treatment.  
Introduction  
 Sensorimotor gating, the regulation of transmission of sensory information to a 
motor system, is disrupted in patients with schizophrenia and manifests as sensory 
overload and cognitive fragmentation (Braff & Geyer,  1990). Prepulse inhibition of the 
acoustic startle response (PPI) is a quantifiable, valid, and reliable response that can be 
measured across species to detect sensorimotor gating deficits (Geyer et al., 2001). PPI is 
the reduction in startle response to an intense stimulus or “pulse” when preceded, up to 
500 ms, by a weaker stimulus or “prepulse”. This neurological phenomenon involves 
forebrain regulation of inhibition on the brain stem startle response. Specifically, the 
nucleus accumbens (NAc) is an integral brain area connecting forebrain and limbic 
structures that modulate PPI (Swerdlow et al., 1990).  
 Dopamine acting on D2-like, D2 and D3, receptors in the NAc can disrupt PPI in 
rats (Wan & Swerdlow, 1993). For example, PPI disruptions were observed after acute 
systemic treatment (Martinez et al., 1999) or direct NAc infusion (Wan & Swerdlow, 
1993) with a D2-like receptor agonist. In contrast to acute treatment, repeated treatment 
with an indirect dopamine agonist resulted in an attenuated PPI disruption in rats (Byrnes 
& Hammer, 2000; Feifel et al., 2002). Repeated treatment with more specific D2-like 
agonists, quinpirole or ropinirole, completely alleviate previous PPI deficits, termed a PPI 
recovery (Berger et al., 2011; Culm & Hammer, 2004). Furthermore, this recovery after 
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repeated treatment is long-lasting as rats continue to display PPI recovery 28 days after 
treatment (Berger et al., 2011).  
The transcription factor ΔFosB is a truncated splice variant of FosB protein and 
with longer stability compared to c-Fos and FosB. It is implicated in long-term behavioral 
adaptation and cellular plasticity (Nestler et al., 2001). ΔFosB was significantly increased 
in the NAc of rats 10 days after repeated D2-like agonist treatment (Chapter 2) and 
blocking the function of ΔFosB prevented PPI recovery (Chapter 2). Therefore, we 
believe that ΔFosB is involved in the preservation of PPI recovery after repeated D2-like 
agonist treatment. This alleviation of a clinically relevant behavior and induction of a 
transcription factor association with behavioral plasticity suggests repeated D2-like 
agonist action may be a therapeutically relevant pharmacological approach to treatment 
for patients with schizophrenia. In order to examine the clinical relevance of repeated D2-
like agonist action, behavioral and pharmacological results must be compared with an 
effective antipsychotic with a similar pharmacological profile.  
Aripiprazole, an atypical antipsychotic, is a D2-receptor partial agonist with 
moderate affinity for several serotonin receptors (Kikuchi et al., 1995). Typical and 
atypical antipsychotics are D2-receptor antagonists and can cause side effects such as 
extrapyramidal symptoms (EPS). In clinical trials, aripiprazole significantly decreased 
reported side effects and patients with first episode psychosis remained on the drug 
longer as compared to older conventional antipsychotics, suggesting adequate treatment 
of positive symptoms (Crespo-Facorro et al., 2013). In early clinical trials aripiprazole 
was suggested to be more effective than older antipsychotics at treatment of cognitive 
and negative symptoms, however these trials had few participants and should be 
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interpreted cautiously (Fleischhacker, 2005; Sato, Yoshimura, Yamashita, Okamoto, & 
Yamawaki, 2012). Larger studies of patients with schizophrenia have found significant 
improvements in working memory (Kim et al., 2012) and verbal memory and fluency 
(Bervoets et al., 2012) after aripiprazole treatment. A Prospective, Multicenter, Open-
Label Study to Evaluate the Effectiveness and the Effect on Cognitive Function of a 
Treatment with Aripiprazole in a Broad Range of Schizophrenia Patients (ESCAPE) 
concluded that switching to or initiating aripiprazole treatment resulted in improvement 
of verbal cognitive functioning (Bervoets et al., 2012). However, other studies have 
found only marginal improvements in cognitive functioning as compared to traditional 
antipsychotics (Yasui-Furukoir, Kaneda, Sugawara, Tomita, & Kaneko, 2012). In human 
and animal research, aripiprazole is efficient at decreasing EPS, however treatment of 
cognitive and negative symptoms of schizophrenia seem hopeful, yet not a cure.  
The possible increased effectiveness and decreased side effects of aripiprazole 
may be due to the unique D2-partial agonist function that results in ‘dopamine 
stabilization’ in the schizophrenic brain (Burris et al., 2002). This stabilization is due to 
the partial agonist’s ability to exert an agonist or antagonist effect on dopamine D2-
receptor containing neurons, thus increasing dopamine effect in hypofunctioning regions 
and decreasing DA effect in hyperfunctioning regions (Kilts et al., 2002; Lawler et al., 
1999). In animal models of schizophrenia, acute aripiprazole treatment attenuates 
apomorphine, a non-specific dopamine receptor agonist, induced PPI deficits, although 
the exact mechanism is unknown (Auclair, Kleven, Besnard, Depoortere, & Newman-
Tancredi, 2006; Nordquist et al., 2008). The effect of acute aripiprazole treatment on D2-
like receptor agonist induced PPI deficits has never been examined, although, 
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aripiprazole is a D2-receptor partial agonist. Furthermore, the effect of repeated 
aripiprazole treatment on D2-like agonist-induced PPI deficits has never been examined 
and the underlying mechanism is unknown.  
Unlike D2 receptor antagonists, we hypothesize the D2 receptor agonist efficacy of 
aripiprazole will alleviate PPI deficits after treatment. Furthermore, we believe 
aripiprazole’s ability to have a D2 agonist effect on neurons in the NAc will mimic our 
previous behavioral and intracellular results after repeated D2-like agonist treatment. We 
predict acute and repeated aripiprazole treatment will alleviate quinpirole-induced PPI 
deficits. Furthermore, if repeated aripiprazole treatment produces PPI recovery after 
treatment, we predict NAc ΔFosB may contribute to the behavioral change.  
Materials and Methods 
Animals and Drug Treatment 
 All animals were housed under a 12:12 h reverse light-dark cycle and given ad 
libitum access to water and food. Rats were allowed to acclimate for 7 days to the 
laboratory before handling and habituation to the behavioral testing chambers. All 
experiments were approved by the Arizona State University and the University of 
Arizona Institutional Animal Care and Use Committees and were conducted in 
accordance with the Guide for the care and Use of Laboratory Animals.  
 Adult male Sprague-Dawley rats (Charles River Laboratories, Hollister, 
California) weighing 260-325 g were habituated to handling and subcutaneous (SC) 
saline injection and placed into a Startle Monitor behavior testing chamber (Kinder 
Scientific, Poway, California) with 70 dB ambient noise for 5 min daily for 2 days before 
baseline testing. Baseline PPI was assessed as described later starting 10 min after 0.9% 
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sterile saline vehicle injection (1.0 mL/kg, SC) on 2 consecutive days to ensure a reliable 
mean value. Treatment groups were normalized according to the mean PPI observed 
during the baseline testing.  
 Aripiprazole, obtained from National Institute of Mental Health's (NIMH) 
Chemical Synthesis and Drug Supply Program, was dissolved in a vehicle of saline and 
0.3% Tween 80 and administered intraperitoneal (IP). Injections were use due to poor 
bio-availability of the drug after oral administration (Nordquist et al., 2008) and dosages 
of 1.0 and 10.0 mg/kg were based on previous findings of these dosages were 
successfully blocked apomorphine-induced hyperlocomotion and PPI deficits (Auclair et 
al., 2006; Nordquist et al., 2008). Quinpirole HCl (Sigma-Aldrich, St. Louis, Missouri) 
was dissolved in vehicle of 0.9% sterile saline and administered SC; dosage was based on 
previous finding of PPI recovery with this dosage (Berger et al., 2011). Vehicle controls 
were 0.9% sterile saline during quinpirole challenges or 0.9% sterile saline dissolved in 
0.3% Tween 80 during repeated aripiprazole treatment. Injections took place in home 
cages.  
Prepulse Inhibition Testing 
 All PPI testing was conducted during the dark phase (900 –1300 h). Each animal 
was placed in a PPI chamber and exposed to 70 dB ambient noise for 5 min, followed by 
a PPI baseline or test session. A PPI baseline session consisted of four consecutive pulse 
trials (120 dB, 40-msec pulses), a randomized presentation of 8 no stimulation, 16 pulse, 
and 15 prepulse (10 each of 73, 76, and 82 dB, 20 msec prepulses, followed 100 msec 
later by a pulse) trials, and ending with four pulse trials. A PPI test session consisted of 
four consecutive pulse trials (120 dB, 40-msec pulses), a randomized presentation of 10 
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no stimulation, 16 pulse, and 30 prepulse (10 each of 73, 76, and 82 dB, 20 msec 
prepulses, followed 100 msec later by a pulse) trials, and ending with four pulse trials. 
The intertrial interval averaged 15 sec (range: 8–22 sec). Percent PPI was calculated as: 
100-[(mean prepulse response/mean pulse response) × 100].  
Acute Aripiprazole Experiment  
Following habituation and baseline normalization of groups, rats received a dose 
of aripiprazole (1.0 or 10.0 mg/kg, (IP) or saline vehicle (1.0 mL/kg)) followed by PPI 
testing. Five days later, rats received a dose of aripiprazole (1.0 or 10.0 mg/kg, IP) or 
saline vehicle (1.0 mL/kg) 30 min prior to a dose of quinpirole (0.1 mg/kg, SC) or saline 
vehicle (1.0 mL/kg) followed by PPI testing.  
Repeated Aripiprazole Experiment 
A separate cohort of rats than the acute aripiprazole experiment, following 
habituation and baseline normalization of groups, received a challenge dose of quinpirole 
(0.1 mg/kg, SC) or saline vehicle (1.0 mL/kg) followed by PPI testing.  The following 
day, rats received daily dose of aripiprazole (1.0 or 10.0 mg/kg, IP) or saline vehicle (1.0 
mL/kg) for 28 consecutive days. Seven days after repeated treatment, rats were given 
another challenge dose of quinpirole (0.1 mg/kg, SC) or saline vehicle (1.0 mL/kg) 
followed by PPI testing. 
FosB/ΔFosB Immunohistochemistry  
 Seven days after the last drug challenge, rats were anesthetized and perfused with 
heparinized saline followed by 4% buffered paraformaldehyde. Brains were post-fixed in 
the same fixative for 2 h at 4° C then placed in graded sucrose solutions in phosphate 
buffered saline (PBS) overnight. Striatal brain sections (20 µm) were mounted on slides, 
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washed three times in 0.05 M potassium phosphate-buffered saline (KPBS, pH 7.4), and 
incubated in 5% normal goat serum/0.05 m KPBS/0.4% Triton X for 60 min at room 
temperature. Primary antibody raised against the N-terminal region of FosB (SC-48; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used at a dilution of 1: 10,000 in 
5% normal goat serum/0.05 m KPBS/0.4% Triton X. This antibody recognizes 32–37 
kDa proteins corresponding to the molecular weight of ΔFosB-like proteins and full-
length FosB (Perrotti et al., 2004). Following incubation for 48 h at 4°C, sections were 
washed three times in 0.05M KPBS and processed using avidin–biotin–peroxidase 
(Vectastain ABC Elite kit, Vector Laboratories, Burlingame, CA, USA). Sections were 
developed with DAB for 5 min, dehydrated and coverslipped at room temperature. 
Control procedures included preabsorption of the primary antibody using FosB peptide, 
and conducting these procedures in the absence of the primary antibody. There was no 
detectable labeling after either of the procedures (not shown). 
Immunohistochemical Analysis 
Tissue sections were examined for the presence of a dark grey reaction product. 
Labeled profiles were obtained from 3-4 sections from each rat. Selected areas of 400 
µm2   within the NAc core, shell, and caudate putamen were captured and digitized using 
a color digital video camera interfaced to a Zeiss Axioskop microscope with a 20X 
objective. Labeled profiles within the areas of interest were determined using 
StereoInvestigator (MicroBrightField Biosciences, Inc., Willston, VT, USA).  A 
systematic random sampling approach using a stereological grid, consisting of 16 equal 
counting frames (100 X 100µm each) ensured randomization of identification within the 
area. A profile was considered labeled if its pixel luminance was more than two standard 
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deviations different from the background luminance as calculated by Stereo Investigator 
software. The average labeled profiles in an area were determined for each animal and 
these data were transformed to express the number of labeled profiles per mm2.  
Statistical Analysis  
Acute aripiprazole PPI, startle response (120dB) and response in the presence of 
ambient noise alone, were analyzed using a one-way analysis of variance (ANOVA). 
Percent PPI (mean ± SEM) are mean values collapsed across three prepulse intensities. 
PPI responses within a single day were analyzed using a one-way ANOVA. PPI 
responses across multiple days were analyzed using two-way repeated-measures 
ANOVA with day of testing as within subject factor and drug treatment as between 
subject factor. ΔFosB labeled profiles were analyzed using two-way repeated measures 
ANOVA with brain area as within subject factor and drug treatment as between subject 
factor. Post-hoc comparisons were made using Fisher’s least squares difference (LSD). 
All data are presented as mean ± SEM and PPI responses are presented collapsed across 
prepulses 3, 6, and 12 dB above ambient noise level (70dB). 
Results  
Startle Response and PPI After Acute Aripiprazole Treatment  
This experiment demonstrates that aripiprazole treatment does not affect startle 
response or PPI. There was no significant difference in startle response (120dB) after 
acute aripiprazole (1.0 or 10.0 mg/kg) treatment (Figure 13). There was also no 
significant difference in PPI response after acute aripiprazole (1.0 or 10.0 mg/kg) 
treatment (Figure 14).  
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Acute Aripiprazole Treatment Prior to Attenuates Quinpirole-Induced PPI Deficits   
 This experiment demonstrates that acute treatment with aripiprazole can attenuate 
quinpirole induced PPI deficits. There was a significant PPI disruption by acute 
quinpirole challenge. However, acute aripiprazole (1.0 or 10.0 mg/kg) treatment 30 min 
prior to quinpirole challenge attenuated quinpirole-induced deficits as compared to 
control rats. Only one dose of acute aripiprazole treatment (10.0 mg/kg) completely 
alleviated the quinpirole-induced deficit as compared to control rats (Figure 15). Neither 
mean acoustic startle (120dB) response nor response in the presence of ambient noise 
alone were altered by acute aripiprazole or quinpirole challenge.  
Repeated Aripiprazole Treatment Alleviates Quinpirole-Induced PPI Deficits 
 This experiment demonstrated that repeated aripiprazole treatment was able to 
attenuate quinpirole-induced PPI deficits. A significant interaction was detected between 
day of quinpirole challenge and drug treatment; this suggests the effect of drug treatment 
is dependent on the day of quinpirole challenge. Further investigation revealed initial 
quinpirole challenge, prior to aripiprazole treatment, significantly reduced PPI as 
compared to control rats. Quinpirole significantly disrupted PPI in rats after repeated 
vehicle treatment; however, repeated aripiprazole (1.0 or 10.0 mg/kg) treatments 7 days 
prior to quinpirole challenge significantly attenuated quinpirole-induced PPI deficits 
treatment (Figure 16). There was no significant effect of aripiprazole treatment on PPI 
(Day 7, 14, 21, 28) during repeated treatment (Figure 17). There was a significant effect 
of drug treatment on response in the presence of ambient noise alone, specifically 
repeated saline animals moved more during no stimulation trials, however there was no 
significant effect of drug on startle (120dB) response on Day 35 of PPI testing.   
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ΔFosB Expression in the Striatum Following Repeated Aripiprazole  
 Modified stereological analysis revealed the higher dose of aripiprazole (10.0 
mg/kg) increased ΔFosB in the striatum 10 days after repeated treatment as compared to 
repeated vehicle treatment (Figure 18). Specifically, ΔFosB labeling in animals after 
repeated aripiprazole (10.0 mg/kg) treatment increased 215% in the NAc core and 140% 
in the NAc shell as compared to repeated vehicle treatment (Figure 19). The lower dose 
of aripiprazole (1.0 mg/kg) failed to increase ΔFosB expression in any region in the 
striatum as compared to vehicle treatment. Furthermore, overall ΔFosB expression was 
increased in the NAc as compared to the CPu and the highest amount of ΔFosB was in 
the NAc core as compared to other sub-regions examined within the striatum.  
Discussion 
Acute Aripiprazole Prevents Quinpirole-Induced PPI Disruption  
 Acute administration of selective D2-like receptor agonists reduces PPI, an 
indication of sensorimotor gating deficits (Culm & Hammer, 2004; Swerdlow, Taaid, et 
al., 1998). In the current study, acute aripiprazole treatment attenuated these deficits in a 
dose response manner and one dose, 10.0 mg/kg, restored quinpirole-induced PPI deficits 
to the response of vehicle treated animals. The ability of acute aripiprazole to attenuate 
PPI deficits has been observed after apomorphine-induced PPI deficits (Auclair et al., 
2006; Nordquist et al., 2008); however in this study, aripiprazole was not able to restore 
PPI to the response of vehicle treated animals. The ability of acute aripiprazole (10.0 
mg/kg) to completely alleviate D2-receptor agonist-induced deficits and attenuate non-
specific dopamine receptor agonist-induced deficits suggests aripiprazole may be more 
effective at targeting the D2-like receptor and preventing PPI deficits through neurons 
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containing these receptors. Acute aripiprazole did not induce any increased movement or 
startle response in rats, possibly reflecting its ability to induce fewer side effects in 
humans (Fleischhacker, 2005).  
Recovery of Sensorimotor Gating Deficits Following Repeated Aripiprazole  
In the current study, repeated aripiprazole (1.0 or 10.0 mg/kg) treatment 
attenuated D2-like agonist induced PPI deficits, which was also observed after acute 
treatment. Furthermore, the quinpirole challenge was 7 days after repeated treatment; 
therefore, aripiprazole was no longer in the system. This finding suggests aripiprazole 
may stimulate similar mechanisms as repeated D2-like agonist treatment resulting in a 
persistent change of a clinically relevant behavior.  
Repeated aripiprazole failed to significantly disrupt startle response, however 
there was a decrease in activity during no stimulus trials among all non-control groups. 
This measurement is not a component of the percentage of PPI; therefore it does not 
directly affect the results. The doses used in this study have not been found to produce 
motor problems (Nordquist et al., 2008) and there was no significant affect detected in 
startle response, which would detect a lack of movement.  
The alleviation of PPI deficits following repeated treatment with quinpirole or 
aripiprazole suggests that D2-like receptor agonist properties of aripiprazole might 
underlie PPI recovery. We believe this because quinpirole challenge dose 7 days after 
repeated treatment failed to disrupt PPI (Berger et al., 2011). Similar behavioral results 
after both drugs allow us to reason that the common D2-like agonist pharmacological 
action is involved in long-lasting behavioral change in the absence of treatment.  
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D2 partial agonists are different than D2-like agonists as evidenced after the acute 
administration of the drug. Acute D2-like agonist treatment produced PPI deficits, 
whereas D2-like partial agonist prevented quinpirole-induced deficits. Acute aripiprazole 
is able to block quinpirole induced disruption because it has a high affinity for the D2-like 
receptor (Nordquist et al., 2008); therefore, it has an antagonizing action at the receptor 
by blocking quinpirole and having less efficacy within the cell resulting in a normal PPI 
response. Therefore, the acute action is very different between D2-like agonist and D2 
partial agonist. Interestingly, when given repeatedly, repeated quinpirole and aripiprazole 
produce the same behavioral effects, possibly by exerting action on the same underlying 
intracellular mechanism involved in preserving a behavioral change.  
ΔFosB in the Striatum Following Repeated Aripiprazole  
To determine if repeated aripiprazole treatment is modifying the same 
intracellular mechanism affected after repeated D2-like agonist treatment, we investigated 
the expression of ΔFosB after repeated D2-like agonist treatment. In the present study, we 
observed ΔFosB expression in the striatum of rats after repeated aripiprazole treatment 
(10.0 mg/kg). ΔFosB expression was not observed in the lower aripiprazole (1.0 mg/kg) 
dose and suggests the partial agonist property of the drug may require a larger dose for 
ΔFosB expression as compared to lower doses of quinpirole (0.1 mg/kg) (Chapter 2). 
However, the lower dose of aripiprazole was able to attenuate PPI deficits. This suggests 
ΔFosB was expressed, but possibly at lower levels than observed with repeated D2-like 
agonist treatment or our procedure for detecting ΔFosB expression is not sensitive 
enough to detect a slight induction. 
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Repeated typical antipsychotic treatments also increase ΔFosB in the striatum; 
however, dense labeling was found throughout the striatum especially in the dorsal 
striatum (Rodriguez et al., 2001). Atypical antipsychotic treatment failed to increase 
ΔFosB expression as compared to typical antipsychotics and labeling was slightly more 
ventral than dorsal (Rodriguez et al., 2001). From these findings, it was suggested that 
dense labeling of ΔFosB in the dorsal striatum after repeated typical antipsychotic 
treatment induced tardive dyskinesia-like behaviors in rodents. In the current study, 
ΔFosB expression was not increased in the dorsal striatum, but was increased in the 
ventral striatum. This suggests repeated aripiprazole treatment is affecting the NAc as 
compared to the dorsal striatum and is supported by the lack of disruption in startle 
response, activity during ambient noise, or PPI after acute aripiprazole. Therefore, we 
believe the novel antipsychotic pharmacological profile of aripiprazole it is more 
effective at targeting brain regions implicated in treatment, such as the NAc, and less 
effective at targeting regions that may induce side effects, such as the dorsal striatum in 
rats.  
ΔFosB expression has been associated with synaptic plasticity in NAc neurons 
after repeated stimuli (Grueter, Robison, Neve, Nestler, & Malenka, 2013). This synaptic 
plasticity may be stimulated after repeated D2-like agonist treatment and aripiprazole 
treatment and contribute to long-lasting changes that prevent pharmacological 
disruptions, such as quinpirole. The similar intracellular findings of ΔFosB expression in 
both aripiprazole and repeated D2-like agonist treatment suggests repeated D2-like agonist 
treatment is activating a mechanism we observe to alleviate PPI deficits, however it may 
also be involved in other symptoms of schizophrenia due to the success of aripiprazole at 
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treating some cognitive symptoms (Sato et al., 2012). Future experiments will test the 
involvement of this underlying intracellular mechanism in regulating cognitive deficits, 
however these similarities suggest factors that contribute to long lasting behavioral 
change after repeated D2-like agonist treatment and aripiprazole may be of potential 
treatment interests.  
The main finding of the current study was that repeated aripiprazole treatment 
attenuated quinpirole-induced PPI deficits and increased ΔFosB labeling in the striatum 
especially in the NAc core. Acute aripiprazole treatment also attenuated quinpirole-
induced deficits and acute or repeated aripiprazole treatment had no effect on startle 
(120dB) response or PPI. These findings combined with previous findings of PPI 
recovery after repeated D2-like agonist treatment (Berger et al., 2011; Culm & Hammer, 
2004; Culm et al., 2004) suggests the D2 receptor agonist properties of aripiprazole may 
underlie sensorimotor gating recovery, a clinically relevant behavior. Furthermore, 
ΔFosB expression in the striatum of aripiprazole treated rats indicates the presence of 
long-term intracellular activity resulting from an antipsychotic and repeated D2-receptor 
agonist treatment. These behavioral and intracellular similarities between an effective 
antipsychotic and repeated D2-like agonist treatment suggests D2-like receptor agonist 
action and factors involved in persistent behavioral change may of clinical interest for 
treatment of cognitive deficits of schizophrenia.  
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Chapter 5 
SUMMARY AND DISCUSSION 
Summary of Experiments  
 Repeated D2-like agonist treatment alleviates prior prepulse (PPI) deficits in rats, 
termed a PPI recovery, and is observable 28 days after treatment (Berger et al., 2011; 
Culm & Hammer, 2004; Culm et al., 2004). The aim of the current project was to 
illuminate the underlying mechanism for long lasting PPI recovery and determine the 
clinical relevance of repeated D2-like agonist treatment. Our results revealed a significant 
increase in ΔFosB in the nucleus (NAc) 10 days after repeated D2-like agonist treatment. 
Additionally, we investigated if ΔFosB was necessary for long-lasting PPI recovery and 
discovered that a bilateral infusion of dominant-negative ΔJunD (ΔFosB antagonist) 
prevented PPI recovery after repeated D2-like agonist treatment. To further develop the 
underlying mechanism of PPI recovery, we observed that dominant negative mutant 
cyclic adenosine monophosphate (cAMP) response element binding (CREB) prevented 
repeated D2-like agonist-induced ΔFosB expression in the NAc. We then compared our 
previous behavioral and intracellular findings to the results of repeated aripiprazole, a 
novel D2-like partial agonist antipsychotic, to determine if repeated D2-like receptor 
agonist action is a clinically relevant pharmacological approach. As compared to previous 
PPI recovery and ΔFosB expression after repeated D2-like agonist treatment, we found 
similar PPI recovery and ΔFosB expression after repeated aripiprazole treatment in rats. 
We can conclude a great deal from these results, therefore critical examination and 
appropriate interpretations are necessary to determine their contribution to already 
established and future schizophrenia research.  
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Discussion   
Underlying Intracellular Mechanism of PPI Recovery after Repeated D2-like 
Agonist Treatment 
  Results of the current experiments demonstrated that ΔFosB in the NAc was 
required for persistent PPI recovery after repeated D2-like agonist treatment. We also 
demonstrated ΔFosB induction was mediated by CREB phosphorylation. These findings 
supplement previous findings of increased PKA activity and phosphorylation of CREB 
after repeated dopamine (DA) D2-like agonist treatment (Berger et al., 2011; Culm et al., 
2004). Together, our results detail an intracellular process regulating PPI recovery.   
We believe this intracellular cascade begins with D2-like receptor activation and 
repeated stimulation does not modify the receptor function (Culm et al., 2004); however, 
the subsequent intracellular components are altered over time. As previously discussed, 
D2-like receptors are Gi coupled protein receptors, in which stimulation of these receptors 
inhibits adenylate cylase. In contrast, repeated D2-like receptor activation results in an 
increase of cAMP through sensitization of adenylate cylcase (Watts & Neve, 2005). 
Increases of cAMP initiates a signal transduction cascade including protein kinase A 
(PKA) and CREB (McClung & Nestler, 2008), We therefore believe activation of the 
cAMP pathway promotes the observed phosphorylation of CREB and increased ΔFosB. 
We believe CREB phosphorylation precedes ΔFosB expression because previous 
examinations observed CREB phosphorylation only immediately after repeated D2-like 
agonist treatment, while ΔFosB expression is observed 10 days after treatment (Berger et 
al., 2011). Increased gene expression after acute DA stimulation is more dependent on 
CREB-dependent whereas increased gene expression following repeated DA stimulation 
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is ΔFosB-dependent (McClung & Nestler, 2003). These results can be explained as 
CREB being constitutively expressed in neurons as compared to ΔFosB, which requires 
time to accumulate after repeated stimulations (Nestler, 2001).  
 Additional support of a relationship between CREB and ΔFosB in the NAc is 
derived from experiments examining chronic cocaine administration or stress exposure. 
After chronic cocaine administration, CREB and serum response factor (SRF) are 
required for ΔFosB induction, whereas only SRF is required after chronic stress in 
resilient mice (Vialou et al., 2012).  These results do not negate the current findings, but 
present a theory that suggests distinct transcriptional mechanisms underlie ΔFosB 
induction after different repeated stimulus. There are currently no studies examining the 
role of SRF after repeated D2-like agonist or antagonist treatment; therefore, it is 
unknown if SRF contributes to ΔFosB after D2-like agonist treatment. Regardless, there 
are alternative explanations why CREB phosphorylation is required for ΔFosB induction 
after repeated D2-like agonist treatment and not for chronic cocaine or stress. 
Repeated D2-like agonist treatment may target different cells and intracellular 
pathways than chronic cocaine or stress. ΔFosB expression is found in D1 containing 
neurons after chronic cocaine and D1 and D2 containing neurons after chronic stress (Kelz 
et al., 1999; Perrotti et al., 2004). We do not believe repeated D2-like agonist treatment is 
affecting D1 containing neurons because NAc D1 receptor-mediated direct pathway does 
not regulate PPI behavior as evidenced by direct infusion of D1 agonist into the NAc 
failing to affect PPI (Wan & Swerdlow, 1993). It is unknown what cells are targeted by 
repeated D2-like agonist treatment. SRF may be required for ΔFosB for in D1 containing 
76 
neurons; however, SRF may not have the same function in D2-like receptor containing 
neurons regulating PPI recovery. Also, repeated D2-like agonist treatments selectively 
target D2-like receptors as compared to cocaine and stress, which indirectly increase 
overall DA levels in the NAc (Abercrombie, Keefe, DiFrischia, & Zigmond, 1989; 
Hernandez & Hoebel, 1988). Therefore, repeated selective D2-like receptor activation 
might selectively increase CREB phosphorylation and ΔFosB expression as compared to 
indirect DA targeting multiple receptors and signaling cascades resulting in other 
transcription factors, such as SRF, being critical for ΔFosB induction. Also, these 
different repeated stimuli might activate different chromatin modifications, which 
influence the production of ΔFosB after SRF, CREB or other factors (Vialou et al., 2012).  
After repeated D2-like agonist treatment, we believe that ΔFosB induction in the 
NAc is required for persistent PPI recovery, observable 28 days after treatment. In the 
current studies, we found ΔFosB expression 10 days after treatment and blocking ΔFosB 
activity in the NAc prevented PPI recovery. This finding further elucidates the role of  
ΔFosB in long-term behavioral change after repeated D2-like agonist treatment, in 
addition to its already established role in chronic stress, drugs of abuse, or natural 
rewards.  
In terms of drug addiction, virtually every drug of abuse administered repeatedly 
induces a long-lasting accumulation of ΔFosB in the NAc (Nestler, 2008). ΔFosB 
increases the rewarding properties of drugs of abuse and may cause the propensity to 
relapse as evidenced by increased sensitization and drug seeking after a period of 
abstinence in bitransgenic mice specifically overexpressing ΔFosB in NAc dynorphin 
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containing neurons (Nestler, 2008). Repeated stress also increases ΔFosB in dynorphin 
and encephalin containing neurons in the NAc and may represent a positive coping 
mechanism as evidenced by ΔFosB overexpression exerting lasting antidepressant-like 
responses (Perrotti et al., 2004). ΔFosB induction after repeated stimulation, such as 
stress or drugs of abuse, can result in the preservation of a behavioral change. This 
supports the conclusion from the current experiments that ΔFosB is necessary for 
persistent PPI recovery.  
The mechanism underlying the ability of ΔFosB to produce long lasting 
behavioral effects is still being investigated, however it has been determined that this 
mechanism involves an increase in dendritic spines and silent synapses, which create an 
optimal condition for long-term potentiation (LTP) (Grueter et al., 2013). These changes 
in dendritic morphology and possible function are believed to be occurring in D1 
containing neurons and affecting the NAc direct pathway. Overexpression of ΔFosB in 
dynorphin containing neurons in mice produced synaptogenesis and silent synapses, 
which was not observed in enkephalin containing neurons (Grueter et al., 2013). Also, 
blocking these changes blocked preference for cocaine, which suggests these adaptations 
are occurring in the reward pathway. We do not believe repeated D2-like agonist 
treatments are targeting the same cells involved in the NAc D1 direct pathway; however, 
synaptogenesis after ΔFosB induction could still be a possible component of long lasting 
PPI recovery. There are two reasons ΔFosB induced plasticity in the NAc may be 
involved in persistent PPI recovery although we do not believe we are targeting the same 
neurons as chronic cocaine.  
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First, PPI is differentially regulated in mice versus rats (Ralph-Williams, 
Lehmann-Masten, Otero-Corchon, Low, & Geyer, 2002). In mice, neurons containing D1 
receptors are believed to be more involved in PPI regulation than D2 containing neurons, 
which is opposite in the rat (Ralph-Williams, Lehmann-Masten, & Geyer, 2003). In the 
previous study using mice, cells containing D1 receptors that are involved in PPI recovery 
may be displaying changes in dendritic morphology after ΔFosB overexpression. 
Therefore, these same neurons in rats, which contain D2-like receptors, have to potential 
to display changes in dendritic morphology after ΔFosB induction, as in PPI recovery. 
Increased dendritic morphology has been found in rats after an increase of ΔFosB in the 
NAc, however the cell types have not been characterized (Pitchers et al., 2013). Second, 
the characterization of D1 or D2 containing neurons based on dynorphin and enkephalin 
expression does not correctly characterize all cells in the NAc. In the NAc, dynorphin and 
D1 are co-expressed and enkephalin and D2 are co-expressed. However, a subset of 
neurons co-expresses dynorphin, D1, and D3 receptors, but not enkephalin (Curran and 
Watson, 1995). Therefore, studies using transgenic mice that overexpress ΔFosB in 
dynorphin-containing neurons may be overexpressing ΔFosB in cells that also express 
D2-like receptors. Furthermore, we have evidence this subset of neurons in the NAc that 
co-express dynorphin, D1, and D3 receptors may be involved in maintaining PPI recovery.  
NAc Neurons Involved in Preserving PPI Recovery  
Repeated D2-like agonist treatment increases PKA activity, CREB 
phosphorylation, and ΔFosB selectively in the ventral striatum (Berger et al., 2011; Culm 
et al., 2004). D1 and D2 containing neurons are located throughout the striatum including 
the dorsal and ventral regions, however D3 containing neurons are mainly located in the 
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ventral striatum (Curran & Watson, 1995). Quinpirole and ropinirole have both been used 
to generate PPI recovery in rats and have high affinity for both D2 and D3 receptors, with 
slightly higher affinity for the D3 receptor (Kvernmo, Hartter, & Burger, 2006; Levant, 
Grigoriadis, & DeSouza, 1992). Therefore, this suggests that the intracellular changes 
after repeated D2-like agonist treatment are possibly stimulating D3 receptors that are co-
expressed on D1 containing neurons. As mentioned previously, a small population of 
neurons in the NAc expresses D1, D3 and dynorphin, but not enkephalin (Curran & 
Watson, 1995). Also, there is growing evidence that D1 /D3 receptors assemble into 
functional heterodimers expressing binding and coupling profiles different from their 
respective monomer profile (Maggio, Aloisi, Silvano, Rossi, & Millan, 2009). In an 
attempt to characterize neurons modulating PPI recovery after repeated D2-like agonist 
treatment, we labeled tissue from rats after repeated D2-like agonist treatment for ΔFosB 
and enkephalin (Figure 20) and distinguished regions expressing enkephalin from ΔFosB 
labeled cells. Due to the difficulty of accurately characterizing dopamine cells based on 
receptor expression, there is limited research on neurons expressing D3 receptors cellular 
function. However, we hypothesize they are vital to the regulation of PPI recovery after 
repeated D2-like agonist treatment.  
In order to validate the hypothesis that a unique population of neurons in the NAc 
regulates PPI recovery, several follow-up studies are needed. First, cells expressing 
ΔFosB after repeated D2-like agonist treatment would need to be characterized. One way 
to characterize these cells is by in situ hybridization for D3 receptor mRNA. In order to 
conclude D3 containing cells are involved in PPI recovery, the same cell would need to 
contain D3 mRNA and express ΔFosB after repeated D2-like agonist treatment. Therefore, 
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in situ hybridization would be combined with immunohistochemistry to make this 
detection. Characterization of neurons affected after repeated D2-like agonist treatment 
may also be possible in mice with transgenic eGFP expression in D1 or D2 containing 
neurons, however currently it is unknown if repeated D2-like agonist treatment has the 
same effect in mice.  If co-labeling were detected, the next step would be to examine 
function of these cells in PPI recovery. This would be very difficult in the rat; however, 
viral vectors may provide the necessary selectivity for targeting D3 containing neurons 
and expressing a dominant negative for ΔFosB that would block its function. This would 
test if ΔFosB in D3 containing neurons is necessary for PPI recovery. If this was 
concluded, it would suggest that neurons co-expressing D1 and D3 receptors might be 
involved in PPI recovery.    
 Future studies are also needed to characterize the progression of events between 
ΔFosB expression and PPI recovery. Experiments examining the presence of dendrite 
morphology and silent synapses after repeated D2-like agonist treatment would determine 
if cellular structure is altered after repeated treatment. Silent synapses can be detected by 
the increased presence of AMPA receptors as compared to NMDA receptors in a given 
area. These amounts can be detected by immunohistochemistry, in situ hybridization, or 
the electrophysiological behavior of the receptor. Furthermore, electrophysiology studies 
would be beneficial to determine if cells that regulate PPI recovery function differently 
after repeated treatments and if this contributes to PPI recovery. For example, the 
detection of excitatory postsynaptic potential (EPSP) or inhibitory postsynaptic potential 
(IPSP) would provide information on the function of the neuron.  If repeated D2-like 
agonist treatment strengthens synaptic connections in the nucleus accumbens indirect 
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pathway, it would suggest that synaptic plasticity is possible in neurons containing D2-
like receptors and as a result the indirect pathway regulating PPI recovery may be more 
efficient. Until this hypothesis is validated, we can speculate on how the intracellular 
mechanisms observed in the current studies affect PPI recovery through the PPI brain 
circuitry.  
Integration of the Underlying Mechanism of PPI Recovery into the PPI Circuit 
 The intracellular changes observed in the NAc after repeated D2-like agonist 
treatment may strengthen synaptic connections from excitatory projections, such as PFC, 
amygdala, or hippocampus; thereby increasing gamma-Aminobutyric acid (GABA)ergic 
activity in the VP via projections from the NAc to the VP (Figure 21). Loss of DA 
function in the NAc following direct infusion of D2-like agonist results in PPI deficits 
(Wan & Swerdlow, 1993). This loss of DA function in the NAc results in decreased 
GABA activity in the VP, which also disrupts PPI, as observed after direct infusion of 
GABA antagonist into the VP (Swerdlow et al., 1990). These projection influences this 
PPI circuitry by exerting a negative modulation of downstream targets by inhibiting the 
outgoing startle response in PPI or closing the “gate”. When this pathway is disrupted, 
the lack of inhibition results in increased startle responses and a PPI deficit. Repeated D2-
like treatments might enhance projections from the NAc to the VP, creating long-lasting 
modifications in the pathway that becomes resilient to future pharmacological 
disruptions. This long-lasting resilience is demonstrated by the inability of quinpirole to 
produce PPI deficits 29 days after repeated D2-like agonist or aripiprazole treatment 
(Berger et al., 2011).  
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Possible Clinical Relevance of Repeated D2-like Receptor Agonist Action 
 In the current studies we investigated the underlying intracellular mechanism of 
PPI recovery following repeated D2-like agonist treatment. We speculated on how this 
intracellular mechanism may produce long lasting modification to brain circuitry 
regulating PPI. PPI is a reliable and valid measurement of sensorimotor gating (Markou 
& Geyer, 1995). Patients with schizophrenia exhibit sensorimotor gating deficits, which 
are associated with cognitive symptoms of the disorder (Swerdlow et al., 1994). 
Therefore, these findings are related to schizophrenia and the underlying mechanism of 
PPI recovery may be of clinical relevance. In the current studies, we examined the 
clinical effectiveness of repeated D2-like receptor agonist function by comparing our 
previous results to an antipsychotic with a similar pharmacological profile, specifically 
the D2-like partial agonist aripiprazole. Aripiprazole alleviated prior PPI deficits 10 days 
after repeated treatment and induced ΔFosB expression in the NAc, similar to repeated 
D2-like agonist treatment. We concluded that repeated D2-like agonist activation might be 
of potential therapeutic interest. However, it is important to examine how repeated D2-
like agonist treatment compares to antipsychotic drugs, which are D2 antagonists.  
 In rats, PPI is a used as a test of clinical efficacy of antipsychotics because of the 
strong correlation between the ability of an antipsychotic to alleviate DA induced PPI 
deficits and later clinical efficacy (Swerdlow et al., 1994). These tests are usually after 
acute antipsychotic administration and do not examine PPI alleviation over repeated 
treatments, therefore we cannot make direct comparisons between our model and 
antipsychotics other than aripiprazole. One experiment did examine the effect of repeated 
antipsychotic treatment on phencyclidine (PCP) induced PPI deficits over 6 days and 
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found atypical antipsychotics were more successful at continuing alleviation as compared 
to typical antipsychotics (Li et al., 2011). Repeated typical antipsychotic administration 
via oral administration significantly increased ΔFosB throughout the striatum as 
compared to limited labeling following repeated atypical antipsychotic administration 
(Rodriguez et al., 2001). The authors concluded that increased ΔFosB expression in the 
dorsal striatum was responsible for antipsychotic side effects because only typical 
antipsychotic treated animals displayed vacuous chewing movements, the animal 
equivalent of tardive dyskinesia in humans. From the limited research on repeated 
antipsychotic treatment in rats, it seems repeated D2-like agonist treatment produces 
behaviors similar to behavioral results after atypical antipsychotics. Although typical 
antipsychotic treatment and repeated D2-like agonist treatment both increased ΔFosB 
labeling in the striatum, we only observed ΔFosB in the ventral striatum and did not 
observe any tardive dyskinesia-like behaviors. The similarity between repeated D2-like 
agonist treatment and atypical antipsychotics might reflect the ability of atypical 
antipsychotics to some extent treat cognitive deficits as compared to typical 
antipsychotics (Stahl, 2007).  
Although clinical effectiveness of antipsychotic drugs can be determined by their 
ability to alleviate DA induced PPI deficits in rats (Swerdlow et al., 1994), the ability of 
antipsychotics to alleviate sensorimotor gating deficits in patients with schizophrenia is 
unclear. Drug naïve patients consistently display PPI deficits, however there is little 
evidence of typical antipsychotics alleviating PPI deficits as compared to some findings 
with atypical antipsychotics (Braff et al., 2001). Interestingly, aripiprazole did not 
alleviate PPI deficits in schizophrenic patients, however it attenuated the deficits 
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significantly more than typical or atypical antipsychotics (Kishi et al., 2010). The 
alleviation of PPI deficits in rodents does not directly translate to humans because DA 
and PCP are used to induce rodent deficits and it is unknown what induces PPI deficits in 
humans. However these findings suggest that aripiprazole may be closer to alleviating 
sensorimotor gating and possibly cognitive deficits in humans.  
Atypical antipsychotics are more effective at treatment of negative and cognitive 
symptoms of schizophrenia compared to typical antipsychotics, but still produce side 
effects. National Institute of Mental Health (NIMH) Clinical Antipsychotic Trails of 
Intervention Effectiveness (CATIE) study found that side effects were the most reported 
reason for discontinuing medication. During this study, 3/4 of patients stopped 
medication before 18 months (Lieberman et al., 2005). This finding suggests 
antipsychotics need to be improved and possibly a new pharmacological approach is 
needed to avoid the unwanted side effects and compliance issues.   
Aripiprazole’s unique pharmacological profile as a D2-partial agonist is a novel 
pharmacological approach as compared to D2 antagonist. Clinical trials suggest the drug 
produces significantly less side effects as compared to typical and atypical antipsychotics 
(Hirose et al., 2004). In the current studies, we believe acute aripiprazole is creating an 
antagonist-like effect at the D2-receptor by binding and blocking quinpirole, however 
after repeated treatment we believe it has an agonist effect at the receptor because it 
prevents PPI disruption, mimicking PPI recovery after repeated D2-like agonist treatment. 
Due to the similar PPI behavior and ΔFosB labeling after a clinically effective 
antipsychotic and repeated D2-like agonist treatment, we can extrapolate that repeated D2-
like agonist treatment might be a possible therapeutic approach.  
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An alternative conclusion to repeated D2-like receptor activation stimulating an 
alleviation of sensorimotor gating deficits, could be that repeated D2-like receptor 
treatment may be inducing an anxiolytic effect in rats that indirectly alleviates 
sensorimotor gating deficits. This conclusion would also be supported by our findings of 
repeated aripiprazole treatment also alleviating sensorimotor gating deficits because 
aripiprazole is also prescribed as an adjunctive therapy in major depressive disorder in 
humans (Spielmans, et al., 2013). In the previous studies, no assessment of stress was 
conducted, however rats were habituated to handling and injections to control for this 
confounding variable. Sensorimotor gating deficits are found in disorders other than 
schizophrenia, however it is not generally found in patients with generalized anxiety or 
depressive disorders (Kohl, Heekeren, Klosterkotter, & Kuhn, 2013); therefore PPI would 
not be the ideal test to detect anxiety or depressive behaviors in rodents. It should be 
noted that stress paradigms, such as maternal separation, can cause PPI deficits in 
rodents, however these models are also used to model sensorimotor gating deficits and 
other behaviors related to symptoms of schizophrenia (Ellenbroek, van den Kroonenberg, 
& Cools, 1998). Also, if repeated D2-like receptor agonist treatment was producing an 
anxiolytic effect, we would believe that rats after treatment would perform better than 
controls, which is not the case with repeated D2-like receptor agonist or aripiprazole 
treatment. The definitive method for determining if repeated D2-like agonist treatment is 
having an anxiolytic effect would be to obtain corticosterone levels from rats during the 
experiment, however due to PPI not detecting depressant or anxiety like behaviors and 
our treatment groups not performing better than controls, we believe at this time repeated 
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D2-like agonist treatment alleviated sensorimotor gating deficits due to its effects 
associated with the cognitive deficits of schizophrenia.  
Although repeated D2-like receptor activation seems like an attractive therapeutic 
option, dosages of such treatment should always be considered. Comparable doses of 
repeated D2-like agonist treatment used in these studies in humans would not be an 
effective treatment for schizophrenia. Patients with schizophrenia have sensorimotor 
gating deficits and assumed dysregulation of neurotransmitter systems, as compared to 
rats that display normal sensorimotor gating before treatment. Acute D2-like agonist 
treatment induces deficits before PPI recovery; therefore, giving an acute treatment to 
attain repeated treatments and intracellular activation would theoretically exacerbate the 
current deficits. Initial low doses that escalate over time, may overcome the acute D2-like 
agonist exacerbation, where eventual stimulation of the underlying intracellular 
mechanism would result in alleviation. This is similar the partial agonist action of 
aripiprazole that has less intracellular effects than D2 agonist or antagonist, however 
when given repeatedly it can cause intracellular change, as observed in the current 
studies. Although repeated D2-like agonist treatment is not a viable treatment for 
schizophrenia, components of the underlying intracellular pathway, which regulates PPI 
recovery, might lead to a potential therapeutic target. The role of ΔFosB in synaptic 
plasticity makes it an attractive target; however, an intervention to increase expression 
would have to be cell-and region-specific because ΔFosB can enhance undesirable 
behaviors. For example, increased expression of ΔFosB in the reward pathway in the 
NAc could increase drug reward and would not be beneficial for schizophrenic patients 
(Nestler, 2008). Therapeutically targeting transcription factors in specific neuron 
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populations is currently not possible in humans; however, scientific advancements in 
research capabilities, such as the use of specialized viral vectors in animals, suggest this 
hypothetical therapy may be a future possibility.  
The goal of the current studies was to elucidate the underlying intracellular 
mechanism for persistent PPI recovery after repeated D2-like agonist treatment and 
determine if it is a therapeutically relevant pharmacological approach. We determined 
ΔFosB induction after CREB phosphorylation was necessary for long lasting PPI 
recovery. Additionally, similar behavioral and intracellular results after aripiprazole 
treatments suggest repeated D2-like agonist treatment is a clinically relevant 
pharmacological approach.  
Final Conclusion 
These findings are important because they propose an alternative approach to 
understanding and treating schizophrenia. This work underscores the importance of 
testing pre-conceived theories a drug’s effect on behavior. For instance, D2-like agonist 
treatment was expected to exacerbate PPI deficits, but repeated treatments unexpectedly 
alleviated PPI deficits and uncovered a potential novel therapeutic mechanism for long-
lasting PPI recovery. From these results, we believe neurons in the NAc projecting to the 
VP may have dynamic capabilities for neural plasticity and may influence cognitive 
functioning. Therefore, further characterization of these neurons may provide valuable 
insight into the causes of cognitive deficits in patients with schizophrenia. In the future, 
components of this underlying mechanism could be targeted to alleviate sensorimotor 
gating deficits, which are not alleviated by current antipsychotic drugs.  Continued 
research into additional factors that sustain this clinically relevant behavior could be used 
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to develop treatments that would produce long lasting behavioral changes after treatment 
in the absence of drugs, which would help address noncompliance issues. This work will 
hopefully aid in the development of effective treatment options that produce fewer side 
effects in order to give patients with schizophrenia the opportunity to live longer lives 
with alleviation of their devastating symptoms.   
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Table 1 
 
Study 1: Drug Effect on PPI Control Measures   
Repeated Drug Treatment  Startle (120dB pulse) (N)  No Stimulus (N)  
Saline      0.828 ± 0.574 0.157 ± 0.085 
Quinpirole       0.522 ± 0.510 0.106 ± 0.091 
Note. p > 0.05, no significant increase in startle and no stimulus trials.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
Table 2 
 
 Study 2: Ropinirole and mCREB PPI Startle Response 
 
 eGFP  mCREB 
 Day 1 Day 28  Day 1 Day 28  
Saline 0.61 ± 0.16 0.75 ± 0.18*  0.35 ± 0.06 0.61 ± 0.10* 
Ropinirole 0.44 ± 0.15 0.71 ±0.22*  0.76 ± 0.23 0.93 ± 0.31* 
Note. Data are expressed in Newtons (N) as mean ± SEM. There was no significant 
effect of ropinirole [F(1,27) = 0.487, p > 0.05] or mCREB [F(1,27) = 0.032, p > 0.05] on 
pulse startle response, however there was an effect over time  [F(1,27) = 27.78, p < 
0.001] using repeated measures ANOVA, treatment groups increased startle response on 
Day 28 as compared to Day 1 (p < 0.05). * p < 0.05 compared to Day 1 startle response 
within treatment group.  
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Table 3 
 
 Study 2: Ropinirole and mCREB on no Stimulus Response 
 
 eGFP  mCREB  
 Day 1 Day 28  Day 1 Day 28  
Saline 0.041 ± 0.006 0.043 ± 0.007  0.055 ± 0.006 0.054 ± 0.008 
Ropinirole 0.04 ± 0.006 0.043 ± 0.006  0.036 ± 0.006 0.040 ± 0.006 
Note. Data are expressed in Newtons (N) as mean ± SEM. There was no significant 
effect of ropinirole [F(1,27) = 1.412, p > 0.05], mCREB [F(1,27) = 0.575, p > 0.05], or 
day F(1,27) = 0.23, p > 0.05] on pulse startle response using repeated measures ANOVA. 
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Table 4 
 
 Study 2: Rostral to Caudal Spread of mCREB Viral Vector  
 
 eGFP   mCREB  
 Left  Right  Left  Right 
Saline 0.54 ± 0.11 0.56 ± 0.11  0.86 ± 0.2 0.57 ± 0.17 
Ropinirole 0.85 ± 0.17 0.77 ± 0.15  0.56 ± 0.15 0.73 ± 0.16 
Note. Data are expressed in mm as mean ± SEM. There was no significant difference 
between side of hemisphere [F(1,24) = 0.499, p > 0.05], mCREB [F(1,24) = 0.062, p > 
0.05], or ropinirole  F(1,24) = 1.05, p > 0.05] and control spread of expressing viral 
vector using repeated measures ANOVA. 
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Table 5 
 
 Study 3: Ropinirole and ΔJunD PPI Startle Response 
 
 eGFP  ΔJunD  
 Day 1 Day 28  Day 1 Day 28  
Saline 0.65 ± 0.14 0.80 ± 0.16*  0.53 ± 0.14 0.60 ± 0.14* 
Ropinirole 0.88 ± 0.28 1.40 ± 0.42*  0.70 ± 0.13 0.96 ± 0.23* 
Note. Data are expressed in Newtons (N) as mean ± SEM. There was no significant 
effect of ropinirole [F(1,24) = 3.163, p > 0.05] or ΔJunD [F(1,24) = 1.597, p > 0.05] on 
startle response using repeated measures ANOVA. There was a significant effect of day 
F(1,24) = 22.99, p < 0.001], treatment groups increased startle response on Day 28 as 
compared to Day 1 (p < 0.05). * p < 0.05 compared to Day 1 startle response within 
treatment group.  
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Table 6 
 
 Study 3: Ropinirole and mCREB on No Stimulus Response 
 
  eGFP  ΔJunD  
 Day 1 Day 28  Day 1 Day 28  
Saline 0.058 ± 0.009 0.071 ± 0.01*  0.046 ± 0.01 0.052 ± 0.012* 
Ropinirole 0.022 ± 0.006 0.027 ± 0.005*#  0.045 ± 0.06 0.047 ± 0.007*# 
Note. Data are expressed in newtons (N) as mean ± SEM. There was no significant effect 
of ΔJunD [F(1,24) = 0.129, p > 0.05] on response during ambient background stimulus 
using repeated measures ANOVA. There was a significant effect of day F(1,24) = 5.617, 
p < 0.05], treatment groups increased startle response on Day 28 as compared to Day 1 (p 
< 0.05). There was a significant effect of ropinirole [F(1,24) = 7.06, p < 0.05], repeated 
ropinirole treatment decreased response (p < 0.05) as compared to controls, however 
there was no effect of virus (p > 0.05) within treatment group. * p < 0.05 compared to 
Day 1 startle response within treatment group. # p < 0.05 compared to control treatment 
on Day 28.  
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Table 7 
 
 Study 3: Rostral to Caudal Spread of ΔJunD Viral Vector  
 
 eGFP  ΔJunD  
 Left  Right  Left  Right 
Saline 0.41 ± 0.12 0.50 ± 0.10  0.47 ± 0.12 0.39 ± 0.08 
Ropinirole 0.50 ± 0.05 0.56 ± 0.05  0.48 ± 0.13 0.38 ± 0.07 
Note. Data are expressed in mm as mean ± SEM. There was no significant difference 
between side of hemisphere [F(1,19) = 0.803, p > 0.05], ΔJunD [F(1,19) = 0.66, p > 
0.05], or ropinirole  F(1,19) = 0.005, p > 0.05] and control spread of expressing viral 
vector using repeated measures ANOVA. 
 
 
 
 
 
 
 
 
111 
Table 8  
 
Study 4: Effect of Drug Treatment on PPI Control Measurements  
 
Drug Treatment  Startle (120dB pulse) (N)  No Stimulus (N)  
S-S-S  0.796 ± 0.622       0.101 ± 0.043a 
S-S-Q 0.419 ± 0.353       0.064 ± 0.031 
Q-A1-Q 0.405 ± 0.253       0.059 ± 0.031 
Q-A10-Q  0.599 ± 0.572       0.067 ± 0.035 
 Note. a p < 0.05 significant increase in no stimulus trial. 
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Figure 1. Diagram of glutamate and dopamine pathways and interactions that contribute 
to positive and negative symptoms of schizophrenia via GABA connections.  
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Figure 2. Prepulse inhibition (PPI) recovery after 28 days of repeated quinpirole 
treatment. Animals were treated daily for 28 consecutive days with quinpirole (0.0, n = 
12; or 0.1 mg/kg, n = 12). Following baseline testing, PPI was assessed 10 min after drug 
treatment on Days 1, 14, and 28. Repeated measures analysis of variance (ANOVA) with 
Sphericity Assumed determined a significant interaction between day of PPI test and drug 
treatment, F(1,14) = 4.779, p < 0.05. Day 1, post-hoc analysis revealed a significant 
effect of quinpirole,  (p < 0.05), treatment on PPI. Day 35, post-hoc analysis revealed no 
significant effect of quinpirole, (p > 0.05). There was also a significant increase of PPI in 
quinpirole treated animals over time (p < 0.05). Percent PPI (mean ± SEM) data were 
collapsed across prepulse levels 3,6 or 12 dB above ambient noise level (70 dB). * p < 
0.05 compared to same day vehicle group. # p < 0.001 compared to Day 1. 
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Figure 3. Repeated quinpirole treatment increased ΔFosB in the NAc core and shell. 
Immunohistochemistry was performed on tissue obtained from rats 7 days after drug 
treatment. Rats were treated with ropinirole (0.0, n = 7; 0.1 mg/kg/day, n = 7) for 28 
days. Repeated measures analysis of variance (ANOVA) with Sphericity assumed 
determined a significant effect of drug treatment across brain areas F(2, 16) = 26.706, p < 
0.001, specifically there was a significantly more ΔFosB labeling within the in NAc core 
and shell (p  < 0.001) as compared to repeated saline treated animals. There was also a 
significant main effect of brain region, F(2, 17) = 76.173, p < 0.001, with the most 
labeling in the NAc as compared to the CPu (p < 0.001). Data are expressed as number of 
nuclear profiles (mean ± SEM) per mm2. * p < 0.001 compared to same day repeated 
saline treated animals in same brain region. 
 
 
 
 
 
 
 
118 
 
 
 
 
 
 
 
 
 
 
 
 
119 
Figure 4. Effect of repeated quinpirole on ΔFosB in the NAc core. (a) ΔFosB positive 
labeled cells after repeated saline treatment. (b) ΔFosB positive labeled cells after 
repeated quinpirole treatment. The anterior commissure is shown at the lower left. 
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Figure 5. Mutant cyclic adenosine monophosphate response binding protein (mCREB) 
prevents prepulse inhibition (PPI) recovery induced by repeated ropinirole treatment. PPI 
was determined three weeks after intracranial infusion of adeno-associated virus for gene 
transfer of enhanced green fluorescent protein (eGFP) or mCREB-eGFP. Rats were 
treated with ropinirole (0.0, 0.1 mg/kg/day, n = 7 per virus group) for 28 days; PPI was 
tested the first and last day of treatment. Percent PPI (mean ± SEM) data were collapsed 
across prepulse levels 3,6 or 12 dB above ambient noise level (70 dB). Repeated 
measures analysis of variance (ANOVA) with Sphericity Assumed determined a 
significant interaction between day of PPI testing and virus/drug treatment [F(3, 54) = 
4.55, p  < 0.01]. Day 1, post-hoc analysis revealed a significant effect of ropinirole,  (p < 
0.05). Day 28, post-hoc analysis revealed a significant effect of ropinirole, (p < 0.05) 
only in mCREB virus infused animals. * p < 0.05 compared to same day saline treated 
group(s). # p < 0.05 compared to eGFP virus infused same drug treatment group.  
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Figure 6. Mutant cyclic adenosine monophosphate response binding protein (mCREB) 
attenuated repeated ropinirole induced ΔFosB expression in the NAc core and shell. 
Immunohistochemistry was performed on tissue obtained from rats 7 days after drug 
treatment. Rats under-went intracranial infusions with adeno-associated virus (AAV) for 
gene transfer of enhanced green fluorescent protein (eGFP) or mCREB-eGFP 3 weeks 
prior to treatment. Rats were treated with ropinirole (0.0, 0.1 mg/kg/day, n = 5 per virus 
group) for 28 days. Repeated measures analysis of variance (ANOVA) with Sphericity 
assumed determined no significant interactions, however there was a significant effect of 
treatment [F(3, 21) = 4.618, p  < 0.05] in the NAc core.  Data are expressed as number of 
nuclear profiles (mean ± SEM) per mm2. * p < 0.05 compared to same brain region, 
eGFP virus infused, repeated saline treated animals. # p < 0.05 compared to same brain 
region, mCREB virus infused, repeated saline treated animals.  
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Figure 7. Mutant cyclic adenosine monophosphate response binding protein (mCREB) 
attenuated repeated ropinirole induced ΔFosB expression in the NAc core 10 days after 
repeated ropinirole treatment and 9 weeks after intracranial infusion with adeno-
associated virus for gene transfer of enhanced green fluorescent protein (eGFP) or 
mCREB-eGFP. Image of ΔFosB labeling in the NAc core after A) eGFP- or B) mCREB-
virus infused after 28 days of repeated ropinirole treatment. Anterior commissure is 
shown at lower right in each illustration. Scale bar: 100 µm. 
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Figure 8. Mutant cyclic adenosine monophosphate response binding protein (mCREB) 
attenuated repeated ropinirole induced ΔFosB in NAc core. Intracranial infusion with A) 
mCREB-eGFP 3 weeks prior to repeated ropinirole induced B) ΔFosB is C) not located 
in the same region within the NAc core. Anterior commissure is shown at lower right in 
each illustration. Scale bar: 100µm.  
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Figure 9. Mutant cyclic adenosine monophosphate response binding protein (mCREB) 
increased ΔFosB in NAc core. Intracranial infusion with A) mCREB-eGFP 3 weeks prior 
to repeated saline increased B) ΔFosB within the NAc core, C) co-expression was 
detected in some, but not all cells. 
 
 
 
 
 
 
 
 
 
 
130 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
A
c
 C
o
re
N
A
c
 S
h
e
ll
C
P
u
0
5
0
0
1
0
0
0
1
5
0
0
m
C
R
E
B
-S
a
li
n
e
m
C
R
E
B
-R
o
p
in
ir
o
le
*
e
G
F
P
-S
a
li
n
e
e
G
F
P
-R
o
p
in
ir
o
le
CREB positive profiles/ mm
2
131 
Figure 10. Mutant cyclic adenosine monophosphate response binding protein (mCREB) 
increased (CREB) in the NAc core. Immunohistochemistry was performed on tissue 
obtained from rats 7 days after drug treatment. Rats were intracranial infusion with 
adeno-associated virus for gene transfer of enhanced green fluorescent protein (eGFP) or 
mCREB-eGFP 3 weeks prior to treatment. Rats were treated with ropinirole (0.0, 0.1 
mg/kg/day, n = 5 per virus group) for 28 days. Repeated measures analysis of variance 
(ANOVA) with Sphericity assumed determined a significant effect of treatment across 
brain areas [F(2, 28) = 5.20, p  < 0.05], specifically there was a significantly more CREB 
labeling within the in NAc core (p  < 0.05) in animals with mCREB virus. Data are 
expressed as number of nuclear profiles (mean ± SEM) per mm2. * p < 0.05 compared to 
same day eGFP virus. 
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Figure 11. Truncated mutant of the JunD protein (ΔJunD) prevents prepulse inhibition 
(PPI) recovery induced by repeated ropinirole treatment. PPI was determined three weeks 
after intracranial infusion of adeno-associated virus (AAV) for gene transfer of enhanced 
green fluorescent protein (eGFP) or ΔJunD-eGFP 3 weeks prior to treatment. Rats were 
treated with ropinirole (0.0, 0.1 mg/kg/day, n = 8 per virus group) for 28 days; PPI was 
tested the first and last day of treatment. Percent PPI (mean ± SEM) data were collapsed 
across prepulse levels 3,6 or 12 dB above ambient noise level (70 dB). Repeated 
measures analysis of variance (ANOVA) with Sphericity Assumed determined a 
significant interaction between day and drug treatment [F(6, 48) = 2.839, p  < 0.05]. Day 
1, post-hoc analysis revealed a significant effect of ropinirole,  (p < 0.05). Day 28, post-
hoc analysis revealed a significant effect of quinpirole, (p < 0.05) only in ΔJunD virus 
infused animals. * p < 0.05 compared to same day vehicle group(s). 
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Figure 12. Truncated mutant of the JunD protein (ΔJunD) increased ΔJunD in the NAc 
core. Immunohistochemistry was performed on tissue obtained from rats 7 days after last 
drug treatment. Rats were intracranial infusion with adeno-associated virus for gene 
transfer of enhanced green fluorescent protein (eGFP) or ΔJunD-eGFP 3 weeks prior to 
treatment. Rats were treated with ropinirole (0.0, 0.1 mg/kg/day, n = 6 per virus group) 
for 28 days. Repeated measures analysis of variance (ANOVA) with Greenhouse-Geisser 
correction determined a significant brain area by treatment interaction [F(6, 28) = 4.67, p  
< 0.05], specifically there was a significantly more JunD labeling within the in NAc core 
(p  < 0.05) in animals with ΔJunD. Data are expressed as number of nuclear profiles 
(mean ± SEM) per mm2.* p < 0.05 compared to same day GFP virus. 
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Figure 13. Startle (120dB) response after acute aripiprazole treatment. Animals were 
treated with aripiprazole (0.0, n = 18; 1.0, n = 8; or 10.0 mg/kg, n = 10) 30 min before 
PPI testing. There was no significant effect of aripiprazole dose [F(2,33) = 0.096, p > 
0.05] on startle response using one-way analysis of variance (ANOVA). 
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Figure 14. Percent prepulse inhibition (PPI) response after acute aripiprazole treatment. 
Animals were treated with aripiprazole (0.0, n = 18; 1.0, n = 8; or 10.0 mg/kg, n = 10) 30 
min before PPI testing. There was no significant effect of aripiprazole dose on [F(2, 33) = 
0.256, p > 0.05] on PPI.  
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Figure 15. Attenuation of quinpirole induced prepulse inhibition (PPI) deficit after acute 
aripiprazole treatment. Animals were treated with aripiprazole (0.0, n = 15; 1.0, n = 7; or 
10.0 mg/kg, n = 8) 30 min before quinpirole (0.0 mg/kg, n = 7) (S-S) challenge; (0.1 
mg/kg, n = 7)  (S-Q); aripiprazole 1.0 mg/kg – quinpirole (A1-Q), n = 7; aripiprazole 
10.0 mg/kg- quinpirole (A10-Q), n = 7) before PPI testing. There was a trending effect of 
drug treatment [F(3, 26) = 2.514, p = 0.08] on %PPI. Furthermore, a planned contrast 
between control and acute quinpirole challenge detected a significant effect t(13)= 2.41, p 
< 0.05, while there was no significant difference between control and acute aripiprazole 
challenge.  * p < 0.05 compared to vehicle animals. 
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Figure 16. Attenuation of quinpirole induced prepulse inhibition (PPI) deficit after 
repeated aripiprazole treatment. Animals were challenged with quinpirole (0.0, n = 30 or 
0.1 mg/kg, n = 30) the day prior to repeated aripiprazole (0.0, n = 30; 1.0, n = 15; or 10.0 
mg/kg, n = 15), 7 days after repeated treatments; animals were challenged again with 
quinpirole (0.0, n = 15 or 0.1 mg/kg, n = 45) before PPI testing. S-S-S, S-S-Q, Q-A1-Q, 
Q-A10-Q, n =15 each group. Repeated measures analysis (ANOVA) with Greenhouse-
Geiesser correction determined a significant interaction between day of quinpirole 
challenge and drug treatment [F(3, 89.753) = 3.945, p  < 0.05]. Day 0, post-hoc analysis 
revealed a significant effect of quinpirole,  (p < 0.05), treatment on PPI. Day 35, post-hoc 
analysis revealed a significant effect of quinpirole, (p < 0.05), in animals that received 
repeated vehicle treatment and no significant effect of quinpirole in animals that received 
repeated aripiprazole treatment (p > 0.05) as compared to control animals. Percent PPI 
(mean ± SEM) data were collapsed across prepulse levels 3,6 or 12 dB above ambient 
noise level (70 dB). * p < 0.05 compared to same day vehicle group(s). 
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Figure 17. Attenuation of quinpirole induced prepulse inhibition (PPI) deficit after 
repeated aripiprazole treatment. Animals were challenged with quinpirole (0.0, n = 30 or 
0.1 mg/kg, n = 30) the day prior to repeated aripiprazole (0.0, n = 30; 1.0, n = 15; or 10.0 
mg/kg, n = 15), 7 days after repeated treatments; animals were challenged again with 
quinpirole (0.0, n = 15 or 0.1 mg/kg, n = 45) before PPI testing. S-S-S, S-S-Q, Q-A1-Q, 
Q-A10-Q, n =15 each group. Repeated measures analysis (ANOVA) with Greenhouse-
Geiesser correction determined a significant interaction between day of quinpirole 
challenge and drug treatment [F(3, 89.753) = 3.945, p  < 0.05]. Day 0, post-hoc analysis 
revealed a significant effect of quinpirole,  (p < 0.05), treatment on PPI. Day 35, post-hoc 
analysis revealed a significant effect of quinpirole, (p < 0.05), in animals that received 
repeated vehicle treatment and no significant effect of quinpirole in animals that received 
repeated aripiprazole treatment (p > 0.05) as compared to control animals. There was no 
significant effect of drug on PPI during repeated treatment. Percent PPI (mean ± SEM) 
data were collapsed across prepulse levels 3,6 or 12 dB above ambient noise level (70 
dB). * p < 0.05 compared to same day vehicle group(s). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
A
c
 C
o
re
N
A
c
 S
h
e
ll 
C
P
u
0
2
0
0
4
0
0
6
0
0
8
0
0
S
-S
-S
S
-S
-Q
Q
-A
1
-Q
Q
-A
1
0
-Q
*
*
*
#
#
!FosB positive profiles/ mm
2
147 
Figure 18. Repeated aripiprazole (10.0 mg/kg) treatment increased ΔFosB in the striatum 
(nucleus accumbens (NAc) Core, shell, caudatoputamen (CPu)). Immunohistochemistry 
was performed on tissue obtained from rats treated for 28 days with aripiprazole (0.0, n = 
9; 1.0, n = 5; or 10.0 mg/kg, n = 6). Repeated measures analysis of variance (Walsh et al.) 
with Spericity Asuumed determined a significant interaction between brain area and drug 
treatment [F(6, 22) = 3.345, p  < 0.05]. There was a significant difference in amount of 
ΔFosB labeling between the three brain regions [F(2, 22) = 52.658, p  < 0.001]. Post-Hoc 
analysis revealed a significant increase of ΔFosB labeling in NAc core as compared to 
other sub-regions (p < 0.05) and significant effect of repeated aripiprazole (10.0 mg/kg) 
treatment   (p  < 0.05) on ΔFosB labeling within each sub-region as compared to repeated 
vehicle treated animals. Data are expressed as number of nuclear profiles (mean ± SEM) 
per mm2. * p < 0.001 compared to same day vehicle group(s). # p < 0.001 compared to 
NAc core. 
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Figure 19. ΔFosB increased in the striatum after repeated aripiprazole (10.0 mg/kg) 
treatment. Image of ΔFosB labeling in the nucleus accumbens (NAc) core from repeated 
(A) saline, (B) aripiprazole (1.0 mg/kg), or (C) aripiprazole (10.0 mg/kg) treated rats 10 
days after treatment. The anterior commissure is shown at the lower left. Scale bar: 100 
µm.   
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Figure 20. Double labeling of enkephalin (green fluorescence) and ΔFosB-like (red 
fluorescence) immunoreactivity in cells of the NAc core after repeated ropinirole 
treatment. Enkephalin and ΔFosB do not seem to be localized in the same areas; a) NAc 
shell b) NAc core, anterior commissure is shown at the lower right.  
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Figure 21. Schematic diagram illustrating the neural substrates regulating prepulse 
inhibition of the acoustic startle response in the rat. This figure emphasizes the 
convergence of dopamine and glutamate projections in the nucleus accumbens (NAc), 
and indicates that intracellular changes in the NAc may modify the outgoing PPI pathway 
(GABA) to the ventral pallidum (VP), which regulates the outgoing startle response 
resulting in PPI recovery following repeated D2-like agonist treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
